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Abstract
Gastric cancer is the fifth most common cancer and the third leading cause of cancer death worldwide.
The majority of patients with gastric cancer are diagnosed with disseminated disease and even patients
diagnosed with early stage disease have high rates
of recurrence. The utility of current mouse models of gastric cancer is limited by slow development of
gastric tumors and lack of metastasis. Here I describe a new mouse model of gastric cancer driven by
p53 loss, Cdh1 loss, and oncogenic Kras expression in
gastric parietal cells (referred to as ACKPY mice). I generated these mice to investigate the contribution
of oncogenic Kras to the progression of gastric cancer given the high rate of mutation and amplification
of the RTK/Ras pathway identified in gastric cancer
patients. These mice develop mixed-type gastric adenocarcinomas with metastases to lymph nodes,
lung, and liver. Oncogenic Kras and loss of Trp53 is sufficient to drive rapid carcinogenesis in a variety of
models. Therefore, I tested if loss of E-cadherin was
necessary for the onset of gastric adenocarcinoma in gastric parietal cells by generating ACKPY mice
with one or two alleles of wild-type Cdh1 (E-cadherin). E-cadherin expression significantly increased
survival and the limited number of mice with gastric
tumors have tumors that were focal in nature, suggesting an additional event was necessary for gastric
tumorigenesis. Loss of E-cadherin expression was observed in some of these tumors, suggesting that its
loss may be necessary for gastric tumorigenesis in this model. I show that loss of E-cadherin in our
model increases β-catenin signaling and that inhibition of β-catenin signaling prolonged survival of
ACKPY mice. Microarray data comparing gene expression in stomachs harvested from Cdh1fl/fl and
Cdh1fl/+ mice showed a correlation between E-cadherin loss and upregulation of oncogenic Kras
signaling. Gene sets regulated by each of the main Kras effector pathways were overrepresented in our
microarray data. Examination of ERK phosphorylation revealed that
E-cadherin likely does not regulate MAPK activity in our model. The upregulation of oncogenic Kras target
genes that result from the loss of E-cadherin may alternatively be explained by E-cadherin regulation of
other Kras effector pathways.
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ABSTRACT

A NEW MOUSE MODEL OF METASTATIC GASTRIC CANCER AND
E-CADHERIN PRIMARY TUMOR SUPPRESSION
Jacob Till
Sandra Ryeom
Gastric cancer is the fifth most common cancer and the third leading cause of cancer
death worldwide. The majority of patients with gastric cancer are diagnosed with
disseminated disease and even patients diagnosed with early stage disease have high rates
of recurrence. The utility of current mouse models of gastric cancer is limited by slow
development of gastric tumors and lack of metastasis. Here I describe a new mouse
model of gastric cancer driven by p53 loss, Cdh1 loss, and oncogenic Kras expression in
gastric parietal cells (referred to as ACKPY mice). I generated these mice to investigate
the contribution of oncogenic Kras to the progression of gastric cancer given the high rate
of mutation and amplification of the RTK/Ras pathway identified in gastric cancer
patients. These mice develop mixed-type gastric adenocarcinomas with metastases to
lymph nodes, lung, and liver. Oncogenic Kras and loss of Trp53 is sufficient to drive
rapid carcinogenesis in a variety of models. Therefore, I tested if loss of E-cadherin was
necessary for the onset of gastric adenocarcinoma in gastric parietal cells by generating
ACKPY mice with one or two alleles of wild-type Cdh1 (E-cadherin). E-cadherin
expression significantly increased survival and the limited number of mice with gastric
tumors have tumors that were focal in nature, suggesting an additional event was
necessary for gastric tumorigenesis. Loss of E-cadherin expression was observed in some
v

of these tumors, suggesting that its loss may be necessary for gastric tumorigenesis in this
model. I show that loss of E-cadherin in our model increases β-catenin signaling and that
inhibition of β-catenin signaling prolonged survival of ACKPY mice. Microarray data
comparing gene expression in stomachs harvested from Cdh1fl/fl and Cdh1fl/+ mice
showed a correlation between E-cadherin loss and upregulation of oncogenic Kras
signaling. Gene sets regulated by each of the main Kras effector pathways were overrepresented in our microarray data. Examination of ERK phosphorylation revealed that
E-cadherin likely does not regulate MAPK activity in our model. The upregulation of
oncogenic Kras target genes that result from the loss of E-cadherin may alternatively be
explained by E-cadherin regulation of other Kras effector pathways.
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CHAPTER 1 INTRODUCTION
i. Abstract
The term gastric cancer generally refers to adenocarcinoma of the stomach, as
approximately 95% of all gastric cancers are adenocarcinomas. Gastric cancer is the fifth
most common cancer worldwide and the third leading cause of cancer death (Jacques
Ferlay et al. 2015; J Ferlay et al. 2013). The majority of gastric cancers are diagnosed
after they have progressed to disseminated disease (Surveillance Research Program, n.d.)
and even patients diagnosed with early stage gastric cancer have relatively poor survival
due to high rates of recurrence (Washington 2010). Since 1965, gastric adenocarcinoma
has been commonly been divided into two main subcategories: intestinal-type and
diffuse-type (Lauren 1965). The progression to intestinal-type gastric cancer follows a
well-described sequence known as the Correa Pathway: inflammation leads to atrophy,
followed by metaplasia, then dysplasia, and finally carcinoma (Correa 1992; Fox and
Wang 2007). While little is known about the histologic and pathologic changes that occur
during the progression to diffuse-type gastric cancer, both sporadic and hereditary forms
are associated with loss of expression of E-cadherin (Graziano, Humar, and Guilford
2003). The mouse has long been used as a model of gastric cancer; initially chemically
induced models and Helicobacter infection models were used, which was followed by the
development of genetically engineered mouse models (Poh et al. 2016; Hayakawa et al.
2013; Yu, Yang, and Nam 2014; Giraud and Judd 2009).
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ii. Gastric Cancer Epidemiology
Gastric cancer is the fifth most common cancer worldwide (fourth among men)
with almost 1 million new cases in 2012 (Table 1-1). The 952,000 new cases diagnosed
in 2012 (6.8% of all malignancies) put it behind only cancers of the lung, breast,
colorectum, and prostate. Greater than 70% of gastric cancer cases occur in the
developing world (677,000 cases in 2012) with more than half in Eastern Asia (549,000
cases in 2012). Incidence rates among men (631,000 cases in 2012) are about twice as
high as those among women (320,000 cases in 2012). Though it ranks as the fifth most
common cancer, with 723,000 deaths (8.8% of all cancer deaths) in 2012 (Table 1-1), it is
the second most deadly among the top 5 cancers, behind lung cancer (Jacques Ferlay et
al. 2015; J Ferlay et al. 2013).
Cancer
Lung
Breast
Colorectum
Prostate
Stomach
Liver
Cervix uteri
Oesophagus
Bladder
Non-Hodgkin lymphoma
Leukaemia
Pancreas
Kidney
Corpus uteri
Lip, oral cavity
Thyroid
Brain, nervous system
Ovary
Melanoma of skin
Gallbladder
Larynx
Other pharynx
Multiple myeloma
Nasopharynx
Hodgkin lymphoma
Testis
Kaposi sarcoma

Incidence
1824701
1671149
1360602
1094916
951594
782451
527624
455784
429793
385741
351965
337872
337860
319605
300373
298102
256213
238719
232130
178101
156877
142387
114251
86691
65950
55266
44247

Mortality
1589925
521907
693933
307481
723073
745533
265672
400169
165084
199670
265471
330391
143406
76160
145353
39771
189382
151917
55488
142823
83376
96105
80019
50831
25469
10351
26974

Table 1-1. Global cancer incidence and mortality by cancer type (2012).
(J Ferlay et al. 2013)
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The incidence of gastric cancer worldwide has declined significantly since 1975
(the first time such statistics were compiled) when it was the most common malignancy
(J Ferlay et al. 2013). In the US, this decline can be observed in the decrease in gastric
cancer mortality since the 1930s (Siegel, Naishadham, and Jemal 2012). Many studies
have shown that this decline is due specifically to a decrease in intestinal-type gastric
cancer, which has been hypothesized to be highly associated with environmental risks.
This decline predates the discovery and treatment of the specific pathogen H. pylori
(which I will discuss later). One hypothesis explaining the decreased incidence in gastric
cancer is the rise in popularity of refrigeration technology (Howson, Hiyama, and
Wynder 1986; La Vecchia et al. 1990). This improved food storage, reduced salt-based
preservation, prevented bacterial and fungal contamination, and allowed greater
incorporation of fresh food and vegetables into the diet.
iii. Gastric Cancer in the Clinic
The signs and symptoms of gastric cancer, if present at all, tend to be vague and
nonspecific in nature. Patients may experience weight loss, anorexia, fatigue, epigastric
discomfort, pain, postprandial fullness, heartburn, indigestion, nausea, or vomiting. None
of these signs and symptoms unequivocally indicates gastric cancer and more commonly
indicate other benign disease. As a result, many patients are diagnosed at late stage. Signs
and symptoms of incurable disease include ascites, jaundice, palpable mass, intestinal
obstruction, ovarian mass (Krukenber’s tumor), peritoneal implant in the pelvis
(Blumer’s shelf), and nodal metastasis around the umbilicus (Sister Mary Joseph’s
Node), to a supraclavicular lymph node (Vichow’s node) or an axillary node (Irish node)
3

(Avital et al. 2015). Data from the Surveillance, Epidemiology, and End Results (SEER)
Program of the National Cancer Institute (NCI) compiled from 2004-2013 show that at
least 60% of patients present with at least regionally invasive disease (Surveillance
Research Program, n.d.).

Percent	
  of	
  Cases	
  

40	
  
30	
  
20	
  
10	
  
0	
  
Localized	
   Regional	
   Distant	
   Unstaged	
  

Figure 1-1. Stage distribution of Surveillance, Epidemiology, and End Results (SEER)
data on gastric cancer from 2004-2013.
(Surveillance Research Program, n.d.)
There are a number of known risk factors for gastric cancer ranging from
environmental to genetic factors. Nutritional risk factors include high salt and nitrate
diets, low dietary vitamin A and C, poor food preparation (smoking, curing), lack of
refrigeration, and poor drinking water (well water). Rubber and coal workers are at
increased risk due to their occupational exposures. Other environmental factors include
H. pylori infection, cigarette smoking, Epstein-Barr virus, radiation exposure, benign
gastric ulcers, and prior treatment for MALT lymphoma. Type A blood, pernicious
anemia, family history (without known genetic factors), Hereditary Nonpolyposis Colon
Cancer, Familial Adenomatous Polyposis, Li-Fraumeni Syndrome, BRCA1/2 mutation,
and Hereditary Diffuse Gastric Cancer are all genetic risk factors for gastric cancer.
4

Finally, several precursor lesions increase the risk of progression to gastric cancer
including adenomatous gastric polyps, dysplasia, chronic gastritis, intestinal metaplasia,
and Menetrier disease (Avital et al. 2015).
In the US, staging follows the traditional TNM staging as defined by the
American Joint Committee on Cancer (AJCC). Increasing stage correlates with increased
mortality. Staging is determined through the use of multiple modalities including physical
exam, endoscopy, biopsy, imaging, and surgery. Notably, stage 1A patients, considered
“curable,” have only a 71% 5-year survival rate (Washington 2010). Recommended
therapy for patients with stage 1 disease is total or sub-total gastrectomy with
lymphadenoectomy. Postoperative chemoradiation is recommended for patients with
stage 1B disease. For all other patients, a combination of palliation, neoadjuvant
chemoradiation, surgery, and adjuvant chemoradiation is recommended based on stage
and medical fitness (Waddell et al. 2013).
iv. Human Gastric Histology
To understand the biology of gastric cancer, it is important to understand the
anatomy and histology of the stomach. The stomach is a large, saccular organ with a
volume of 1.2-1.5 liters and a capacity of more than 3 liters. Food enters the stomach
from the esophagus passing through the gastro-esophageal junction and exits the stomach
via the pyloric sphincter where it enters the duodenum. The stomach is subdivided into 5
regions: the cardia, the fundus, the corpus (body), the antrum, and the pyloruos (Figure
1-2A). The gastric wall (from inner to outer) is composed of the mucosa, submucosa,
muscularis propria, and serosa. The mucosa and submucosa are thrown into folds called
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rugae. The inner surface of the mucosa is perforated by millions of foveollae or gastric
pits that lead to the gastric glands. The mucosa is composed of the surface epithelium,
lamina propria, and muscularis mucosa. Gastric adenocarcinoma arises from this surface
epithelium (Figure 1-2B).
The more superficial compartment of the gastric mucosa is called the foveolar
compartment. It is primarily composed of columnar mucous cells and is relatively
uniform through the stomach. The foveolar layer consists of the more superficial mucous
cells, which secrete mucins and the deeper, less mucinous, mucous neck cells, which are
thought to give rise to both the foveolar and the deeper glandular compartments (Figure
1-2C).
The deeper glandular compartment is composed of gastric glands. The glands
vary in their composition of four main cell types depending on the region of the stomach.
The four main cell types are mucous cells, parietal cells, chief cells, and endocrine cells.
Parietal cells are the acid producing cells, pumping hydrogen ions out into the lumen in
exchange for potassium ions. Parietal cells are also important for their production of
secreted signals that regulate the differentiation and maintenance of gastric progenitors.
They are typically located in the superficial half of the glandular layer, appearing large
and pale pink on hematoxylin & eosin (H&E) staining. Chief cells produce and secrete
pepsinogens (proteolytic proenzymes). They are typically located in the lower half of the
glandular layer, appearing smaller and dark purple on H&E stain. Endocrine cells are
scattered throughout the gastric glands and appear triangular shaped with brightly pink
granules on H&E stain. They are characterized by the hormones they secrete; some of the
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most common endocrine cells are gastrin-producing G cells, somatostatin-producing D
cells, and endothelin-producing X cells (Adler, Farraye, and Crawford 2015) (Figure
1-2C).

Figure 1-2 Normal gastric histology.
(A) Schematic view of human stomach regions
(B) Schematic diagram of stomach wall
(C) Schematic diagram of a gastric pit/gland
v. Mouse Gastric Histology
The mouse stomach has some notable differences from the human stomach that
must be kept in mind when discussing mouse models of gastric cancer. Whereas the
human stomach is relatively uniform in its histology, the mouse stomach is subdivided
into two sections. The proximal third comprises the non-glandular forestomach that is
squamous and esophageal in morphology. The distal two-thirds is referred to as the
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glandular stomach and is analogous to the human stomach. A projecting fold, called the
limiting ridge, demarcates these two regions. The glandular stomach is analogous to the
human stomach and is similarly divided into anatomic regions that differ in their
glandular cellular content: cardia, corpus, pyloric antrum (Scudamore 2013) (Figure 1-3).

Figure 1-3. Schematic view of mouse stomach regions
vi. Gastric Cancer Histologic Classification
The term gastric cancer refers to adenocarcinoma of the stomach, as
approximately 95% of all gastric cancers are adenocarcinomas. Since 1965 gastric
adenocarcinoma has been commonly divided into two main subcategories: intestinal-type
and diffuse-type (Lauren 1965). The World Health Organization (WHO) subdivides these
categories further and adds other subtypes. The intestinal-type is characterized by the
formation of glands or tubules. WHO tubular and papillary adenocarcinoma fall into this
category. The diffuse-type is characterized by single cells or small clusters of cells that
are poorly cohesive and do not form glands. Signet ring cells, so called for the large
mucin droplet that displaces and flattens the nucleus to one side, are pathognomonic of
diffuse-type gastric cancer. WHO poorly cohesive carcinoma and mucinous
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adenocarcinoma fall into this category. More recently, a third category referred to as
“mixed-type” has been added to the Lauren classification to include neoplasms with both
intestinal- and diffuse-type characteristics (Lauwers 2015).
Intestinal-type gastric cancer is found more commonly in areas of the world with
a higher incidence of gastric cancer and is the subtype that has declined the most rapidly
in the past few decades. Additionally, it is more common among older individuals and
men. Diffuse-type gastric cancer rates are more homogenous across the world, the
incidence has declined more slowly, and it occurs with similar frequency between the
sexes and throughout all age groups. These data suggest that the intestinal-type is more
highly associated with environmental factors, whereas the diffuse-type is less
environmentally associated (Muñoz and Asvall 1971).
Though both types are associated with H. pylori infection, little else is known
about the histologic and pathologic changes that occur during the progression to diffusetype gastric cancer. The progression to intestinal-type gastric cancer follows a welldescribed sequence known as the Correa Pathway (Figure 1-4) (Correa 1992; Fox and
Wang 2007). This progression begins with chronic inflammation (gastritis) often due to
the specific pathogen H. pylori. The inflammation leads to epithelial defects including
gland dilation and mineralization in addition to the infiltration of lymphocytes. It is
followed by an atrophic gastritis that is characterized by loss of parietal cells and focal
fibrosis. The definitions of atrophic gastritis and intestinal metaplasia often overlap;
however, the loss of parietal cells in atrophic gastritis is considered mechanistically
important. Loss of acid production (achlorhydria) leads to bacterial overgrowth and loss
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of secreted signals dysregulates growth and differentiation of progenitors. This is
followed

by

intestinal

and/or

pseudopyloric/spasmolytic

polypeptide-expressing

metaplasia (SPEM). Intestinal metaplasia is characterized by a transition from normal cell
architecture to an elongated intestinal phenotype with mucous droplets and occasionally
the formation of goblet cells. SPEM has recently been recognized as more closely
associated with progression to gastric cancer and it has been suggested to be the true
precursor lesion. It is a type of mucous metaplasia that, as the name suggests, is
characterized by expression of spasmolytic polypeptide. This is followed by dysplasia
with irregular glandular architecture characterized by infolding and branching as well as
cellular and nuclear atypia. The final stage is frank carcinoma with invasion (Fox and
Wang 2007) (Figure 1-4).

Figure 1-4. Correa pathway (Fox and Wang 2007).
vii. Hereditary Diffuse Gastric Cancer
Genetically engineered mouse models are generated utilizing common or
hereditary genetic lesions to induce cancer; this has been the case with gastric cancer as
well. In 1964, Jones reported on the case of a 21-year-old Maori male with an inoperable
carcinoma of the stomach. This was particularly interesting because of the man’s young
age and the high incidence of the disease in close relatives (five with proven gastric
cancer and several others suspected) (Jones 1964). This kindred was updated in 1998 by
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Guilford et al to include an additional 25 cases of gastric cancer that had occurred since
the initial report (Guilford et al. 1998). Jones termed this phenomenon “early onset
familial gastric cancer,” but it would come to be known as “Hereditary Diffuse Gastric
Cancer” (HDGC). The inheritance pattern observed in the Maori kindred was one of
dominant inheritance with incomplete penetrance (Guilford et al. 1998), consistent with a
susceptibility gene as observed in other hereditary cancer syndromes (Nagy, Sweet, and
Eng 2004).
Using classical genetic mapping techniques, Guilford and colleagues mapped the
genetic locus to chromosome 16q22.1, which contains the candidate gene for E-cadherin
(CDH1). E-cadherin is a calcium dependent cell-cell adhesion protein important for
establishing cellular polarity and maintaining normal tissue morphology. Loss of
expression of E-cadherin is found in many cancers and correlates with infiltrative and
metastatic ability; therefore, it has been termed an “invasion suppressor gene” (A. O. O.
Chan 2006). Single-stranded conformational polymorphism screening of coding exons
revealed a band shift in exon 7 in two affected and 4 obligate carriers that was not present
in 150 unrelated chromosomes. Upon direct sequencing, the first causal mutation
(G1008T) was identified. This mutation, in the final nucleotide of an exon, removes the
splice site. Guilford et al identified an additional frame shift mutation and premature stop
codon in two additional families with HDGC. The disease appears to follow a classic
two-hit sequence as expression of E-cadherin is lost in HDGC tumors. However, unlike
many other inherited cancer syndromes, this loss is frequently due to promoter
hypermethylation rather than loss of heterozygosity. Further, CDH1 hypermethylation
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and loss of expression is found in the majority of sporadic cases of diffuse-type gastric
cancer (Graziano, Humar, and Guilford 2003). Interestingly, H. pylori infection has been
shown to modulate promoter methylation of CDH1 (Liu et al. 2014).
The risk of gastric cancer in patients with HDGC-associated mutations has been
estimated at approximately 70% (67% in men and 83% in women) with an additional risk
of lobular breast adenocarcinoma in women of 52% (Guilford, Humar, and Blair 2010;
Kaurah et al. 2007). Over 100 different CDH1 mutations have been identified with no
characteristic mutational types or hotspots. HDGC patients typically present with diffusetype gastric adenocarcinoma with signet ring cells and linitis plastica (at late stage) that is
indistinguishable from sporadic forms of diffuse-type gastric cancer. The only option for
patients with known HDGC to prevent cancer is prophylactic total gastrectomy.
However, this option comes with significant morbidity including alteration of eating
habits, dumping syndrome, diarrhea, and weight loss. Surveillance endoscopy is a poorly
favored option as even advanced diffuse-type gastric cancer can be missed due to its
often-subtle appearance. Current recommendations are for prophylactic total gastrectomy
prior to 20 years of age when mortality risk from surgery and mortality risk from HDGC
are about equal at <1% (Guilford, Humar, and Blair 2010).
While E-cadherin has been identified as the genetic hit in HDGC, the exact
mechanism by which a mutation leads to gastric cancer is still not known. Several
mechanisms have been proposed to explain E-cadherin’s tumor suppressor activity
including sequestration of β-catenin, regulation of Rho GTPases, interaction with EGFR,
and inhibition NF-κB. E-cadherin sequesters β-catenin at the adherens junction in the
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cadherin-catenin complex that links the adherens junction to the cytoskeleton. Loss of Ecadherin may lead to increased free β-catenin, which can translocate to the nucleus, bind
its transcription factor partners and transcribe classical WNT pathway target genes.
Further, E-cadherin regulates Rho GTPases involved in cell motility and migration. Ecadherin has also been shown to interact with EGFR and act in a context-dependent
manner to activate or inhibit its signaling. Finally, E-cadherin can inhibit the activity of
NF-κB likely through binding and sequestering its p65 subunit (Liu et al. 2014).
viii. Gastric Cancer Molecular Classification
Two

recent

studies

have

attempted

to

molecularly

classify

gastric

adenocarcinomas using high-throughput genomic technologies. The Cancer Genome
Atlas Research Network (TCGA) analyzed a panel of 295 treatment-naïve gastric
adenocarcinoma samples for: copy number variation, whole-exome sequencing,
methylation profiling, RNA sequencing, microRNA sequencing, and reverse-phase
protein array, and microsatellite instability (MSI). Integration of the results of
unsupervised clustering on each platform classified the samples into four groups (Bass et
al. 2014). The first TCGA group was associated with high Epstein-Bar virus (EBV)
burden and promoter hypermethylation. The second group had high MSI, mutation rates,
and promoter hypermethylation. The remaining samples were divided into two groups
based on the degree of copy number variation. Further analysis defined four similar subtypes based on EBV positivity (9%), high MSI (22%), genomic stability (GS, 20%), or
chromosomal instability (CIN, 50%). Each sub-type was further characterized by its
associated mutational spectrum, notable pathway/gene activation or inactivation, and
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histologic type. The GS sub-type contained 73% of the diffuse-type gastric cancer
samples and was associated with CDH1 and RHOA mutations. The CIN group was
associated with intestinal morphology, TP53 mutation, and receptor tyrosine kinase
(RTK)-RAS activation (Figure 1-5) (Bass et al. 2014).
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Figure 1-5. Summary of The Cancer Genome Atlas (TCGA) gastric cancer subtypes
(Poh et al. 2016; Bass et al. 2014).
The Asian Cancer Research Group (ACRG) analyzed a panel of 291 primary
gastric tumors for: expression profiling, copy number variation, and targeted gene
sequencing. For this classification, principal components analysis separated the samples
into three clusters. The first was positively correlated with an epithelial-to-mesenchymal
transition (EMT) signature and negatively correlated with a cell proliferation signature.
The second correlated with MSI, cytokine signaling, cell proliferation, and methylation
signatures. The remaining cluster of samples were subdivided based on their TP53
activation status, resulting in four subtypes: MSI, microsatellite stable (MSS)/EMT,
MSS/TP53+, and MSS/TP53-. Each sub-type had distinct genomic alterations, survival
outcomes, and recurrence rates. The authors note that the MSS/EMT subtype was
predominantly (80%) diffuse-type. However, it only contained 27% of the diffuse-type
samples and the highest rate of CDH1 mutation was in the MSI group. The highest
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percentage of EGFR and ERBB2 (HER2) amplifications were found in the MSS/TP53group, but the highest rate of KRAS mutation was in the MSI group (Figure 1-6)
(Cristescu et al. 2015).
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Figure 1-6. Summary of Asian Cancer Research Group (ACRG) gastric cancer subtypes
(Poh et al. 2016; Cristescu et al. 2015).
ix. Animal Models of Gastric Cancer
To advance our understanding of the cellular and molecular mechanisms
underlying gastric cancer progression and to develop new treatments, there is a need for a
mouse model that better replicates advanced human disease. Three types of mouse
models have traditionally been used: chemically induced models, helicobacter induced
models, and genetically engineered models. These models have also been combined into
hybrid models to study their interactions and to accelerate or advance disease
progression. However, current animal models of gastric cancer do not adequately
recapitulate advanced disease because of long latency periods and the lack of metastatic
disease or the presence of metastasis only to regional nodes (Hayakawa et al. 2013;
Giraud and Judd 2009; Poh et al. 2016; Yu, Yang, and Nam 2014).
The earliest mouse model of gastric cancer is the N-methyl-N-nitrosourea (MNU)
induced model (Tatematsu et al. 1992). However, most mice died due to squamous cell
carcinomas (SCC) of the forestomach prior to adenocarcinoma development in the
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glandular stomach. Reducing the dose of MNU in the drinking water produced
adenocarcinomas without the confounding forestomach SCCs (Tatematsu et al. 1993;
Yamachika et al. 1998). The MNU model has been utilized in combination with
genetically engineered mice to investigate many signaling pathways involved in gastric
cancer, including p53 (Yamamoto et al. 2000), E-cadherin (Humar et al. 2009), β-catenin
(Takasu et al. 2008), and NF-κB (Sakamoto et al. 2010) (Table 1-2). More recently, two
chemically induced models of precancerous change have come into use: the parietal cell
specific protonophore DMP-777 and the structurally related L-635 (Hayakawa et al.
2013). DMP-777 was first used in rats (Goldenring et al. 2000), but in both rats and mice
it causes acute oxyntic atrophy, mucous cell hyperplasia, and SPEM (Goldenring et al.
2000; Nomura et al. 2005). In contrast, treatment with L-635 is more rapid and has the
additional feature of a prominent inflammatory infiltration (Nam et al. 2010).
Other mouse models of gastric cancer attempted to utilize the specific pathogen
H. pylori as it is known to contribute to gastric carcinogenesis in humans. In the late
1980s it was shown that mice are resistant to infection with the human pathogen H. pylori
(Ehlers, Warrelmann, and Hahn 1988; Cantorna and Balish 1990), so the feline isolate H.
felis (A Lee et al. 1990) or H. pylori mutant strains have been used instead (Adrian Lee et
al. 1997). H. felis infection produces gastritis and atrophy with some strain dependence
(A Lee et al. 1990; A Lee et al. 1993; Sakagami et al. 1996). Prolonged infection leads to
hyperplasia, metaplasia, and dysplasia leading to adenocarcinoma (Fox et al. 2002).
Results of infection with the commonly used Sydney strain of H. pylori (SS1) are strain
specific, it causes gastritis and atrophy but no carcinoma at 23 months in C57BL/6 and
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Balb/cA mice (Xin Wang et al. 2003) but causes intra-mucosal cancer at 15 months in
B6.129 mice (Rogers et al. 2005). Infection with H. felis or H. pylori strains have also
been used in conjunction with MNU (Tomita et al. 2011; Han et al. 2002) and genetic
models of gastric cancer (T. C. Wang et al. 2000; Fox et al. 2002).
Genetic Model
Trp53+/+ vs. +/- vs. -/-

Finding
Ref
-/Higher incidence of tumors in Trp53 mice.
(Yamamoto
No Trp53 mutations in the tumors of any group
et al. 2000)
+/+
+/Cdh1 vs. Cdh1
Equal incidence of intestinal-type adenoCA.
(Humar et
Diffuse-type was 11x more common in Cdh1+/-. al. 2009)
K19-C2mE Tg
β-catenin accumulation in pyloric but not fundic (Takasu et
± H. pylori SS1
tumor cell cytoplasm and nuclei.
al. 2008)
β-catenin mutations were more common in H.
pylori associated tumors.
Ikkβfl/fl vs. IkkβΔFoxa3 Decreased tumorigenesis with KO of Ikkβ.
(Sakamoto
Increased apoptotic cell death in Ikkβ KO.
et al. 2010)
Apoptosis was dependent on decreased IL1α.
Table 1-2. Relevant compound MNU-induced/genetically engineered models.
The age of transgenic mouse models has seen a plethora of genetically engineered
mouse models (GEMMs) of gastric cancer. There are 24 models that result in at least
intra-mucosal gastric cancer and more that model pre-neoplastic changes (Poh et al.
2016; Hayakawa et al. 2013; Yu, Yang, and Nam 2014; Giraud and Judd 2009). The long
latency and lack of metastasis in the majority of these models limit their utility. Relevant
to our studies are the models that utilize deletion of Cdh1 and activate oncogenic Kras as
well as the more recent models that attempt to define the cell of origin of gastric cancer.
As described earlier, germline mutations in the Cdh1 gene (encoding E-cadherin)
are responsible for HDGC. In 2011, Mimata et al attempted to model HDGC using the
Cdh1 conditional allele and a gastric parietal specific Cre, Atp-4b-Cre. The Atp4b
promoter was first used in 1995 to drive SV40 T antigen expression to study pre-parietal
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cell biology (Q. Li, Karam, and Gordon 1995). Similar experiments generated
neuroendocrine tumors when expression of a conditional SV40 T antigen allele was
driven by Atp-4b-Cre expression (Syder et al. 2004).
The Cdh1 conditional deletion resulted in hyperplasia that progressed from 3
months on but no invasive cancer by two years. However, they did observe signet ring
cells (pathognomonic of diffuse gastric cancer) at 12 months (Mimata et al. 2011). In
2012, Shimada et al. added conditional deletion of the tumor suppressor Trp53 and found
that these double-conditional knockout mice developed intra-mucosal tumors at 6 months
and invasive tumors at 9 months with a median survival of one year. At this one-year
time point, 40% of mice had local lymph node metastasis (Shimada et al. 2012).
Early studies of the role of oncogenic Kras in gastric cancer utilized the Keratin
19 (CK19) promoter to drive expression throughout the gastrointestinal tract. One report
described parietal cell atrophy and mucous neck cell hyperplasia at 3-6 months of age
(Brembeck et al. 2003). At 16 months, invasive intestinal-type adenocarcinomas were
observed (Okumura et al. 2010). Another group bred the conditional KrasLSL-G12D to a
CK19-CreERT transgene to produce tamoxifen-inducible oncogenic Kras expression. This
study observed only hyperplasia, metaplasia, and adenomas of the stomach, however the
lack of frank carcinomas may have been due to the increased mortality seen in these
mice. Over half the mice had to be euthanized prior to the 6 month endpoint due to
weight loss correlated with oral tumors (Ray et al. 2011). Expression of oncogenic
KrasLSL-G12D under the control of the ubiquitous promoter UBC9-CreERT drove severe
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inflammation, hyperplasia, metaplasia, and carcinogenesis in the stomach, but other
organs were devoid of neoplastic changes (Matkar et al. 2011).
Several groups have recently argued that Mist1+ or Lgr5+ stem cells are the cell of
origin of both intestinal-type and/or diffuse-type gastric cancer. The evidence they cite is
their ability to drive tumorigenesis by specific genetic manipulation of these cell types
using cre/lox technology (Hayakawa et al. 2015; X. Li et al. 2016). However, at least in
the case of diffuse-type gastric cancer, similar manipulations of gastric parietal cells
using Atp-4b-Cre results in tumor formation (Shimada et al. 2012). This suggests that
several cells of origin exist, that this is not the right criterion on which to identify tumorinitiating cells, or that some overlap may exist between these cell populations.
x. Conclusion
Though a plethora of mouse models of gastric cancer exist, none adequately
recapitulates the advanced disease as is seen in the majority of human patients. These
models have long latencies, lack metastasis, or metastasize only to regional nodes. To
advance our understanding of the cellular and molecular mechanisms underlying gastric
cancer progression and to develop new treatments for gastric cancer, there is a need for a
mouse model that better recapitulates advanced human disease.
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Model
CEA/SV40

Incidence
100%

Duration
50 d

Location
Antrum

Type
Intestinal

Inv
Y

Met
N

MMTV/Ad12

3–4 m

SCJ

N

Antrum

Y

Y

(Searle
1994)

CA-AhR

100%

246 d(F)
352 d(M)
12 m

Intestinal
Adenosquamous
Carcinoid

Y

HPV-16

82%(M)
17%(F)
100%

Corpus

Intestinal

Y

N

Atp-4b/SV40

100%

12 m

Corpus/Antrum

Neuroendocrine

Y

Y

Atp-4b/Cdx2

100%

100 w

Corpus

Intestinal

Y

N

INS-GAS

75%

20 m

Corpus

Intestinal

Y

N

ACT-GAS

100%

20 m

Corpus

Intestinal

N

N

GAS−/−

60%

12 m

Antrum

Intestinal

N

N

13%

18 m

Antrum

Intestinal

N

N

30%

5m

Antrum

Intestinal

Y

N

100%
100%

18 m
10 m

Corpus/Antrum
SCJ

Intestinal
Intestinal

Y
Y

N
N

100%

3m

Antrum

Adenoma

N

N

38%

16 m

Corpus

Intestinal

Y

N

100%

20 w

SCJ

Intestinal

Y

N

(Andersson et al.
2002)
(Syder et al.
2004)
(Mutoh et al.
2004)
(T. C. Wang et
al. 2000)
(Konda et al.
1999)
(Zavros et al.
2005)
(Tsuzuki et al.
2001)
(Lefebvre et al.
1996)
(Xu et al. 2000)
(Nam
et
al.
2012)
(Tebbutt et al.
2002)
(Okumura et al.
2010)
(H. Oshima et al.
2006)

100%

12 m

Corpus

Diffuse

Y

Y

(Shimada et al.
2012)

29%

20 m

Antrum

Intestinal

N

N

(Qiang Li et al.
2012)

1/6

7 mo

Antrum

ND

Y

N

2005(Redman et
al. 2005)

ND

4 mo

Corpus

Intestinal

N

N

(Hayakawa et al.
2015)

78%

18 m

ND

Diffuse

N

N

(Hayakawa et al.
2015)

ND

9m

ND

Diffuse

Y

N

(Hayakawa et al.
2015)

40%

3m

Corpus

Intestinal

Y

N

(X. Li
2016)

et

al.

ND

3m

Corpus/Antrum

Intestinal

Y

N

(Thiem
2016)

et

al.

MTH1

−/−

TFF1−/−
+/−

Smad4
Smad3−/−
Gp130Y757F/Y757F
K19/Kras

G12V

K19/Wnt1
K19/C2me
Atp4b-Cre
Cdh1fl/fl
p53fl/fl
Villin-Cre
KLF4fl/fl
Elf+/−
Smad4+/−
Mist1-CreERT2
KrasLSL-G12D
Apcfl/fl
Mist1-CreERT2
Cdh1fl/fl
H. felis
Mist1-CreERT2
Cdh1fl/fl
LSL-p53R172H
H. felis
Lgr5-CreERT2
Smad4fl/fl
PTENfl/fl
Gp130Y757F/Y757F
Tff1-CreERT2
KrasLSL-G12D

(Ref)
(Thompson et al.
2000)
(Koike et al.
1989)
et

Table 1-3. Genetically Engineered Mouse Models (GEMMs) of gastric adenocarcinoma.
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CHAPTER 2 ACKPY METASTATIC MODEL OF GASTRIC CANCER
i. Abstract
The utility of current mouse models of gastric cancer is limited by slow
development and lack of metastasis (Poh et al. 2016; Hayakawa et al. 2013; Yu, Yang,
and Nam 2014; Giraud and Judd 2009). Here I describe a new mouse model of gastric
cancer driven by p53 loss, Cdh1 loss, and oncogenic Kras expression in gastric parietal
cells. I generated these mice to investigate the contribution of oncogenic Kras to the
progression of gastric cancer given the high rate of mutation and amplification of the
receptor tyrosine kinase (RTK)/Ras pathway in gastric cancer. These mice develop
invasive diffuse and intestinal type gastric adenocarcinomas as early as 6 weeks of age
and die with metastases to the lymph nodes, lung, and liver by 3 months. The rapid
disease progression allows for timely analysis of tumor biology, diagnostics, and
therapeutics while the metastatic phenotype makes it highly relevant to human disease.
ii. Introduction
The utility of current mouse models of gastric cancer is limited due to the long
latency periods for tumor development, the lack of metastasis in these models or
metastasis only to regional nodes in a few models (Poh et al. 2016; Hayakawa et al. 2013;
Yu, Yang, and Nam 2014; Giraud and Judd 2009). To date, there are six mouse models of
metastatic gastric cancer (Table 2-1). However, only one has clinical relevance. Two
utilize the SV40 transgene that plays no role in human cancer (Thompson et al. 2000; Q.
Li, Karam, and Gordon 1995; Syder et al. 2004). One utilizes human papilloma virus
(HPV)-16 (Searle et al. 1994) that is not associated with gastric cancer in humans
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(Kamangar et al. 2006). A fourth utilized adenovirus 12 (Koike et al. 1989) and a fifth
utilized a constitutively active dioxin/aryl hydrocarbon receptor (Andersson et al. 2002),
neither of which has ever been shown to be involved in the development of gastric
cancer. Further, the lesions found in the adenovirus 12 model were adenosquamous
lesions of the forestomach, which is consistent with esophageal disease and not
adenocarcinoma of the stomach (Koike et al. 1989). The only model that contains genetic
lesions identified in human disease is the double conditional deletion of the Cdh1 and
Trp53 genes, but only 40% of mice have local nodal metastasis. A mouse model that
better replicates advanced human disease would advance our understanding of the
cellular and molecular mechanisms underlying gastric cancer progression.
Model
CEA/SV40

Incidence
100%

ATP-4b/SV40

Duration
50 d

Phenotype
Intestinal

12 months

Neuroendocrine

HPV-16

100%

246–352 d

Carcinoid

MMTV-Ad12

56%

4 months

Adenosquamous

CA-AhR

100%

12 m

Intestinal

CDH1/p53

100%

12 m

Diffuse

Metastasis
Invasion to the
duodenum
LN
Liver
LN
Liver
LN
Lungs
Invasion of
local organs
LN (40%)

Reference
(Thompson et al. 2000)
(Q. Li, Karam, and
Gordon 1995; Syder et
al. 2004)
(Searle et al. 1994)
(Koike et al. 1989)
(Andersson et al. 2002)
(Shimada et al. 2012)

Table 2-1. Metastatic mouse models of gastric cancer (LN = Lymph Node).
The H+/K+ ATPase pump, found only in gastric parietal cells and pre-parietal cells
is responsible for the acidification of the stomach. The Atp4b gene encodes the beta
subunit and has been used to alter expression of various genes in this cell population
(Syder et al. 2004). One such model is the conditional deletion of the Cdh1 gene in
gastric parietal cells by use of the Atp4b-Cre allele in Cdh1fl/fl mice. These mice
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developed signet ring-like cells at 12 months of age but no invasive cancer even at 24
months (Mimata et al. 2011). Shimada et al added a conditional deletion of Trp53
resulting in invasive diffuse-type gastric cancer by 9 months, with 40% of mice
developing metastasis to regional lymph nodes at one year (Shimada et al. 2012). We
have attempted to overcome the limitations of this model by adding a third genetic hit.
In the TCGA cohort, the RTK/Ras signaling axis is altered in the majority of
gastric cancer samples. EGFR family members (EGFR, ERBB2, ERBB3 and ERBB4) are
amplified or mutated in 44% (126/287) of cases. The Ras family is genetically modified
in 18% (46) of cases and, of those, 14% (36) are specifically KRAS alterations. In fact,
KRAS is mutated in 9% (23) of all cases and the vast majority (20) of these mutations are
known oncogenic mutations (18 in codons 12/13, 2 in codon 61). Additionally, RASA1, a
negative regulator of Ras, is mutated or deleted in 9% (24) of cases. Finally, the Raf
family is modified in 14% of cases (Figure 2-1) (Bass et al. 2014; Cerami et al. 2012).
Activation of this pathway has been modeled in several studies. Oncogenic Kras
activation has been shown to produce precancerous or cancerous lesions in the mouse
stomach in a promoter-dependent manner (Ray et al. 2011; Okumura et al. 2010; Matkar
et al. 2011).
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A

B
C
D
E
Figure 2-1. Genetic alterations of the RTK/Ras/Raf axis in gastric cancer.
(Bass et al. 2014; Cerami et al. 2012) (A) EGFR family, (B) Ras family, (C) RASA1, (D)
Raf family, (E) Symbol key.
Based on these data, we investigated the contribution of oncogenic Kras towards
the progression of gastric cancer. I generated a mouse model of gastric cancer driven by
gastric parietal cell-specific (Atp-4b-Cre) loss of E-cadherin (Cdh1fl/fl), loss of p53
(Trp53fl/fl), and expression of oncogenic Kras (KrasLSL-G12D/+). Additionally, I included a
yellow fluorescent protein (YFP) reporter allele (Rosa26LSL-YFP). These mice will
hereafter be referred to as ACKPY mice (Figure 2-2).

Figure 2-2. Schematic of ACKPY mouse model genetics.
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iii. Results
Addition of oncogenic Kras to Cdh1/Trp53 deletion model decreases survival four-fold

Figure 2-3. Survival and weight phenotypes of ACKPY (KrasG12D/+) mice compared to
ACPY (Kras+/+) mice.
(A) Kaplan-Meier survival curve of ACKPY (n=20) and ACPY (n=19) mice (B) Weight
graph of corresponding mice over time.
Characterization of the ACKPY mouse model revealed a rapid course of disease.
The mice had a median survival of 76.5 days (range 64-91 days, SD 7.2). This was over
four times faster than the ACPY controls (wild-type Kras, Cdh1 loss and Trp53), which
had a 322-day median survival (range 272-386 days, SD 32.8, Figure 2-3A). ACKPY
mice began to lose weight around 60 days of age and disease progression correlated with
weight loss (Figure 2-3B).
ACKPY mice rapidly develop mixed-type gastric cancer with linitis plastica
At necropsy, stomachs were dramatically enlarged with normal stomach replaced
by tumor. They displayed classic linitis plastica (i.e. leather bottle stomach) with
thickened, rigid, and whitened gastric walls (Figure 2-4A). Histologically, the gastric
cancers that developed in these mice were mixed-type, with regions consistent with both
diffuse- and intestinal-type morphology (Figure 2-4B). In one human cohort, mixed-type
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gastric cancer accounted for 15% of cases (with 54% intestinal- and 32% diffuse-type)
(Polkowski et al. 2016).

Figure 2-4. Gross and histologic phenotype of ACKPY tumors.
(A) Representative gross images of wild-type and ACKPY stomachs (scale bar: 1 cm).
(B) Representative images of intestinal- and diffuse-type lesions found in ACKPY mice.
(C) Representative H&E and immunofluorescent (blue: DAPI, yellow: YFP) images of
ACKPY and Cre- control stomachs harvested from mice at 3, 6, and 9 weeks of age
(scale bar: 1 mm).
We examined the kinetics of disease progression in this model by analyzing
stomachs of ACKPY mice and Cre- (CKPY) controls at 3, 6, and 9 weeks of age. As
expected, Cre- control stomachs displayed normal architecture at all time points (Figure
2-4C). ACKPY mice had few or no identifiable gastric parietal cells by 3 weeks of age
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and 100% of mice demonstrated high-grade dysplastic lesions and/or intra-mucosal
carcinomas. At this time point, immunofluorescence microscopy for YFP+ recombined
cells revealed clusters of transformed cells. By 6 weeks of age, there was a dramatic
increase of these lesions with invasion in 40% of mice. By 9 weeks of age all mice had
invasive carcinomas (Figure 2-4C).
Metastatic disease in ACKPY mice
Ten mice were sacrificed at 64-83 days of age and analyzed for metastasis to local
lymph nodes, liver, and lungs. Upon gross examination of the abdomen under a
fluorescent dissecting microscope (Figure 2-5A), the stomach was enlarged and YFP+
nodules were apparent within the perigastric fat in all mice. Histologic evaluation of the
perigastric fat identified these nodules as perigastric lymph node metastases (Figure
2-5C). Though no gross lesions were observed in the liver, immunofluorescent histologic
analysis of tissue specimens identified micro-metastatic lesions in 20% of mice (Figure
2-5D).
Gross examination of the thoracic cavity identified YFP+ lesions in the
mediastinum adjacent to the trachea in 50% of mice examined (Figure 2-5B).
Histologically these were confirmed as mediastinal lymph node metastases (Figure 2-5E).
YFP+ lung metastases were identified in all mice (Figure 2-5F). In 50% of mice these
lung metastases could be observed grossly, while the remaining 50% harbored micrometastases only identifiable by immunofluorescent microscopy.
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Figure 2-5. Metastatic phenotype of ACKPY mice.
(A&B) Representative gross and fluorescent images of the abdomen or thoracic cavity,
(C,D,E,F) H&E and immunofluorescent (blue: DAPI, yellow: YFP) images of metastatic
lesions in ACKPY mice. Scale bars are all 1 mm except for the liver that is 0.5 mm.
I successfully isolated four independent cell lines from four different primary
gastric tumors and one from a local lymph node metastasis. All cell lines tested formed
flank tumors in wild-type C57BL/6 mice (Figure 2-6A), experimental validation of the
neoplastic nature of these lesions. One of the two gastric cancer-derived cell lines tested
metastasized to the lung in an experimental model of spontaneous metastases (Figure
2-6B).
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Figure 2-6. Metastatic ACKPY cell line.
(A) Growth curve of primary tumor cell line injected subcutaneously into the flank of
naïve mice (5x106 cells/mouse, n=4). Data are presented as the mean tumor volume ±
SD. (B) H&E image of lung metastases (red arrows) derived from an ACKPY gastric
cancer flank tumor.

ACKPY model depends on MAPK activity downstream of oncogenic Kras

Figure 2-7. Kaplan-Meier survival curve of ACKPY mice treated with MEK inhibitor.
Mice were treated beginning at 4 weeks of age with MEK inhibitor PD0325901
administered ad libitum in the mouse chow at 7 mg/kg of diet.
To test the dependence of our model on oncogenic Kras signaling through the
MAPK pathway, I treated mice with an inhibitor to the downstream kinase MEK
(PD0324901). These mice had an increase in median survival of 18.5 days over vehicle
(p=0.001, n=8). Of note, one mouse survived over 200 days on treatment (Figure 2-7).
These data support the utility of the ACKPY model for testing preclinical compounds in
the treatment of gastric cancer.
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iv. Discussion
This newly generated ACKPY mouse model of gastric cancer represents a highly
tractable and clinically relevant mouse model for the field of gastric cancer research.
More recently, several additional groups have used specific promoters to drive oncogenic
Kras expression in the stomach (Table 2-2). Of the four studies that expressed oncogenic
Kras alone, three of them demonstrated precancerous changes (Ray et al. 2011; Matkar et
al. 2011; Thiem et al. 2016). One group examined mice at 16 months (Okumura et al.
2010) and found gastric cancer in less than 40% of mice. Two recent genetic models
utilize oncogenic Kras and an additional genetic lesion (Apc deletion or Gp130
activation) to drive cancer development (Hayakawa et al. 2015; Thiem et al. 2016).
However, one does not invade (Hayakawa et al. 2015) and neither metastasizes
(Hayakawa et al. 2015; Thiem et al. 2016). Our ACKPY model is clinically relevant,
invasive, and metastasizes widely.
Model
CK19-CreERT
KrasLSL-G12D
UBC9-CreERT
KrasLSL-G12D

Incidence
ND

Duration
6m

Location
ND

Type
Adenoma

Inv
N

Met
N

(Ref)

ND

13-18 d

Mucus
Gland
Metaplasia

N

N

(Matkar
2011)

et

al.

Tff1-CreERT2
KrasLSL-G12D
K19/KrasG12V

ND

9m

Fore/Glandular
Stomach
Junction
Corpus/Antrum

Adenoma

N

N

(Thiem
2016)

et

al.

38%

16 m

Corpus

Intestinal

Y

N

Mist1-CreERT2
KrasLSL-G12D
Apcfl/fl
Gp130Y757F/Y757F
Tff1-CreERT2
KrasLSL-G12D

ND

4 mo

Corpus

Intestinal

N

N

(Okumura et al.
2010; Brembeck
et al. 2003)
(Hayakawa et al.
2015)

ND

3m

Corpus/Antrum

Intestinal

Y

N

(Ray et al. 2011)

(Thiem
2016)

et

Table 2-2. Oncogenic Kras driven mouse models of precancerous and cancerous gastric
disease.
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Both the increased rate of tumor formation and the increased metastasis observed
in the ACKPY model over the ACPY model is genetically attributable to the inclusion of
an oncogenic Kras allele. To test the dependence of our model on oncogenic Kras
signaling through the MAPK pathway, I treated mice with an inhibitor to the downstream
kinase MEK. While this treatment significantly increased survival (median survival of 95
days compared to 76.5 days for untreated) it did not do so to the level of genetic
exclusion of the oncogenic Kras allele as seen in ACPY mice (median survival of 1 year).
This discrepancy may be due to one or more of several explanations. First and
foremost, inhibitor treatment was initiated at 4 weeks of age, a time at which small
tumors are already present. Thus, the context of MAPK inhibition is completely different
than MAPK activity resulting from lifelong germline wild-type Kras activity. For
example, drug resistance could evolve quickly within already established tumors to
overcome the MEK inhibition. Second, there is no reason to think the level of
MEK/MAPK activity in the Kras wild-type context (ACPY) would be equivalent to the
level of inhibited activity in the oncogenic Kras context (ACKPY+inhibitor). Inhibition
is not perfect and the dosage may have been too low; allowing for a degree of MAPK
signaling to still be present in the inhibited ACKPY tumors that is higher than the level of
MAPK signaling in the ACPY stomachs. Finally, as will be discussed in future chapters,
the MAPK pathway is not the only pathway downstream of oncogenic KRAS. Simple
inhibition of one downstream pathway in the context of oncogenic Kras would not be
expected to be equivalent to the genetic inhibition of all downstream pathways in the
context of wild-type Kras (as is the case in ACPY mice).
31

Our findings also have implications for the gastric cancer cell of origin debate.
Hayakawa et al (2015) showed that activation of oncogenic Kras and loss of Apc in
Mist1+ stem cells was sufficient to drive intestinal-type gastric cancer, indicating that this
population may be the cell or origin for intestinal-type gastric cancer. Further, because
they were able to drive tumorigenesis by loss of Cdh1 and H. felis infection in this cell
population, they argued that Mist1+ stem cells are the cell of origin of diffuse-type gastric
cancer. However, Li et al (2016) found that Lgr5+ stem cells are the cell of origin of
intestinal-type gastric cancer by showing that deletion of Smad4 and PTEN in this
population led to tumor formation. By these criteria, our data driving mixed-type gastric
cancer in pre-parietal cells or parietal cells (those that express Atp4b) (Q. Li, Karam, and
Gordon 1995) suggests that they are also a cell of origin for both intestinal-type and
diffuse-type gastric cancer.
These conflicting data may be resolved by further investigation of the overlap
between these lineages and their progeny. Lgr5+ stem cells (Barker et al. 2010) and
Mist1+/Troy+ stem cells (Stange et al. 2013) have been shown to generate all cell types in
the gastric glands, including parietal cells. Perhaps it is not the Lgr5+ or Mist1+ stem cells
that are being transformed, but their parietal cell or pre-parietal cell differentiated
daughter cells. Further experimentation is necessary to test this hypothesis.

As proof of principle of the model’s utility, we have begun to investigate the role
of the microbiome in our model. As has been shown in many cancers, but particularly
those of the alimentary tract, the microbiome plays an important role in the development
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of disease (Ohtani 2015). We treated our ACKPY model with a commonly utilized
quadruple antibiotic cocktail to deplete the microbiota. Microbiome depletion was
confirmed by qPCR for the bacterial 16S ribosomal subunit in stomach and cecal
contents at necropsy (Figure 2-8B). Though the results are preliminary, microbiome
depletion resulted in a 7.5-day increase in median survival (p=0.04, n=6) over vehicle
(n=5) (Figure 2-8A). While the specific pathogen H. pylori is known to contribute to
pathogenesis of gastric cancer, these data implicate the normal microbiota in gastric
cancer development.

Figure 2-8. Antibiotic depletion of microbiome increases ACKPY survival.
(A) Kaplan-Meier curve showing 7.5-day increase in median survival (p=0.04,) for
antibiotic treated mice (red, n=6) over vehicle (black, n=5). (B) Microbiome depletion as
measured by qPCR for the bacterial 16S ribosomal subunit (normalized to total DNA
content) in stomach (p=0.02) and cecal (p<0.0001) contents at necropsy. Antibiotics were
administered via the drinking water ad libitum at 1 g/L ampicillin, 1 g/L neomycin, 1 g/L
metronidazole, 0.5 g/L vancomycin, and 4 g/L sucralose.

Given the metastatic phenotype of the ACKPY model, we wished to determine if
we could detect circulating tumor cells (CTCs) and if their presence would correlate with
any of the metastatic phenotypes. We used flow cytometry to measure CTCs in cardiac
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blood by counting the number of YFP+ cells present (CTCs defined as DAPI-, CD45-,
YFP+). These data are preliminary but promising; mice with many CTCs (>90 per 100 μl
blood) were found to have macro-metastatic disease of the lung, whereas mice with few
CTCs (<15 per 100 μl blood) did not (Table 2-3). These data indicate a promising avenue
of future research and the utility of the model in the burgeoning field of CTCs.
Animal

CTCs per
Macroscopic
100 μl
Lung
blood
Metastases
1
338
Yes
2
111
Yes
3
95
Yes
4
13
No
5
11
No
6
11
No
7
2
No
Table 2-3. Number of circulating tumor cells (CTCs) correlates with lung metastasis
phenotype.
CTCs defined as DAPI-, CD45-, YFP+ cells per 100 µl blood.
This model offers the potential to investigate the molecular mechanisms driving
gastric cancer via both the E-cadherin pathways and the RTK/Ras signaling axis, and
may also serve as a useful model for testing new therapies targeting both primary gastric
cancer and metastatic lesions. Both the rapid progression of gastric cancer and
widespread metastases set it apart from other available mouse models of gastric cancer.
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CHAPTER 3 E-CADHERIN AS GATEKEEPER TO MUTANT KRAS AND P53
LOSS-DRIVEN GASTRIC CANCER
i. Abstract
Expression of oncogenic Kras and loss of Trp53 is sufficient to drive rapid
development of lung cancer (Jackson et al. 2005), pancreatic ductal adenocarcinoma
(Bardeesy et al. 2006), squamous cell carcinoma (Caulin et al. 2007), acute myeloid
leukemia (Z. Zhao et al. 2010), and undifferentiated pleomorphic sarcoma (Kirsch et al.
2007; Mito et al. 2009) in the mouse. To determine if loss of E-cadherin was necessary
for the onset of gastric adenocarcinoma or if oncogenic Kras and loss of Trp53 in gastric
parietal cells were sufficient to drive tumorigenesis I generated ACKPY mice with either
one or two alleles of wild-type Cdh1 (E-cadherin). E-cadherin expression significantly
increased survival and the gastric tumors that did arise were more focal in nature
compared to Cdh1fl/fl mice, suggesting an additional event is necessary for gastric
tumorigenesis. Loss of E-cadherin expression was observed in some of these tumors,
suggesting that its loss may be necessary for gastric tumorigenesis in this model.
ii. Introduction
Conditional expression of oncogenic Kras and Trp53 deletion have been used to
model many types of cancer in the mouse. Expression of oncogenic Kras in the pancreas
is sufficient to drive carcinogenesis (Hingorani et al. 2003). In the mouse lung, oncogenic
Kras alone drives adenoma formation that rarely progresses to adenocarcinomas (Johnson
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et al. 2001). Addition of Trp53 loss or mutation accelerates these processes (Jackson et
al. 2001; Jackson et al. 2005; Hingorani et al. 2005; Bardeesy et al. 2006). Expression of
oncogenic Kras alone in the mouse skin (Caulin et al. 2007) and hematopoietic system (I.
T. Chan et al. 2004; Braun et al. 2004) results in the development of precancerous
lesions, while addition of Trp53 loss or mutation results in carcinoma and leukemia,
respectively (Caulin et al. 2007; Z. Zhao et al. 2010). Finally, expression of oncogenic
Kras and loss of Trp53 can also drive a mouse model of undifferentiated pleomorphic
sarcoma (Kirsch et al. 2007; Mito et al. 2009) (Table 3-1). Given the sufficiency of
oncogenic Kras and deletion of Trp53 to drive tumorigenesis in multiple cell types, I
investigated whether Cdh1 loss was necessary in our ACKPY model to drive
carcinogenesis in gastric parietal cells or if expression of oncogenic Kras and deletion of
Trp53 were sufficient for the development of gastric adenocarcinoma.
There is evidence in other Kras/Raf1 mouse models of cancer that loss of Cdh1 is
either required for high penetrance tumorigenesis or that its loss enhances tumorigenesis.
Oncogenic Kras and Cdh1 deletion in combination have been shown to increase tumor
formation in a liver tumorigenesis model. Though both oncogenic Kras and loss of Cdh1
individually were sufficient to drive tumor formation in a minority of mice, the
combination of both lesions resulted in 100% incidence of tumors, higher-grade disease,
increased invasiveness, and intrahepatic metastasis (Table 3-2). The authors argued that
loss of E-cadherin leads to an epithelial-mesenchymal transition phenotype, up-regulation
of stem cell marks, and an increased ERK activation (Nakagawa et al. 2014). In a mutant
Raf-driven model of non-small cell lung cancer (NSCLC) the additional loss of E36

cadherin resulted in the progression of adenomas to adenocarcinomas with increased
vascularity, invasiveness, and micro-metastasis to local lymph nodes (Table 3-2). They
identified β-catenin signaling resulting in increased vascular endothelial growth factor
(VEGF) expression as the key mediator of this phenotype (Ceteci et al. 2007).
Model
Lung

Pancreas

Skin

Blood

Sarcoma

Genetics
KrasG12D-LA
KrasG12D-LA
Trp53+/-, -/Adeno-Cre (intra-nasal)
KrasLSL-G12D
Adeno-Cre (intra-nasal)
KrasLSL-G12D
Trp53fl/+,fl/fl,R172H/+.R172H/fl,R270H/+,R270H/fl
Pdx1-Cre
KrasLSL-G12D
Pdx1-Cre
KrasLSL-G12D
Trp53LSL-R172H/+
Pdx1-Cre
KrasLSL-G12D
Trp53fl/+,fl/fl
K5.Cre
KrasLSL-G12D
TPA
K5.Cre
KrasLSL-G12D
Trp53LSL-R172H/+
TPA
K5.Cre
KrasLSL-G12D
Trp53fl/fl
TPA
Mx1-Cre
KrasLSL-G12D

Phenotype
Adenoma, Adenocarcinoma
Accelerated progression

Reference
(Johnson et al.
2001)

Adenoma, Adenocarcinoma

(Jackson et al.
2001)
(Jackson et al.
2005)

LGshp53CreER
KrasLSL-G12D
Adeno-Cre (intra-muscular)
KrasLSL-G12D
Trp53fl/fl

Acute Myeloid Leukemia

Accelerated progression

PanIN
PDAC
Accelerated progression

(Hingorani et al.
2003)
(Hingorani et al.
2005)

Accelerated progression

(Bardeesy et al.
2006)

Benign Papilloma

(Caulin
2007)

et

al.

Spindle Cell Carcinoma

Squamous Cell Carcinoma

Myeloproliferative Disorder

Undifferentiated
Pleomorphic Sarcoma

(I. T. Chan et
2004; Braun
al. 2004)
(Z. Zhao et
2010)
(Kirsch et
2007; Mito et
2009)

Table 3-1. Oncogenic Kras and Kras/Trp53 driven mouse models of cancer.
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Model
Liver

Genetic
Alb-Cre
KrasLSL-G12D

Hepatocellular Carcinoma
(HCC)

Liver
Intra-hepatic
cholangiocarcinoma
(IHCC)

Lung
Non Small Cell Lung
Cancer (NSCLC)

Alb-Cre
Cdh1fl/fl
Alb-Cre
KrasLSL-G12D
Cdh1fl/fl
Alb-Cre
KrasLSL-G12D
Alb-Cre
KrasLSL-G12D
Trp53fl/+
Alb-Cre
KrasLSL-G12D
Trp53fl/fl
SP-C C-RAF BXB
SP-C-rtTA
Tet-O-Cre
Cdh1fl/fl
SP-C C-RAF BXB
SP-C-rtTA
Tet-O-Cre
Cdh1fl/fl

Phenotype
-4/10 with tumors @ 8 mo
-dysplastic nodules or
well-differentiation HCC
-2/12 with tumors @ 11 mo
-HCC (α-fetoprotein+)
10/10 with tumor @ 8 mo
-HCC (α-fetoprotein+)
-typical trabecular type type to
poorly differentiated type
-1/8 died of IHCC by 75 wks
-Died at 36 wks
-75% died of IHCC by 75 wks
-Median Survival 52 wks

(Reference)
(Nakagawa et
al. 2014)

(O’Dell et al.
2012)

-100% died of IHCC by 30 wks
-Median Survival 19 wks
-Adenomas by 6 weeks
-No tumors @ 10 mo
-Diffuse hyperplasia
-Enlarged alveolar spaces
-No inflammation
-Increased tumor volume
-Increased vascularity
-Increased invasiveness
-Micro-metastases

(Ceteci et al.
2007)

Table 3-2. Kras/Raf and Cdh1 driven models of cancer.
iii. Results
Cdh1fl/+ and Cdh1+/+ mice live significantly longer than Cdh1fl/fl mice
The presence of one or two Cdh1 wild-type alleles dramatically increases survival
(p<0.0001, Figure 3-1) in comparison to Cdh1fl/fl (ACKPY) mice. Of 37 Cdh1fl/+ mice,
only 7 died naturally between 67 and 123 days. Similarly, out of 36 Cdh1+/+ mice, only 6
died naturally between 72 and 133 days. In comparison, a cohort of 20 Cdh1fl/fl mice
survived to endpoint between 64 and 91 days of age. However, theses data are
confounded by cutaneous tumors in the remaining 30 Cdh1fl/+ mice and 30 Cdh1+/+ mice.
These large tumors required euthanasia of the mice prior to gastric cancer endpoints.
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Figure 3-1. Kaplan-Meier curve showing increased survival of Cdh1fl/+ and Cdh1+/+ as
compared to Cdh1fl/fl mice. Mice euthanized for cutaneous tumor are displayed as
censored events.

Figure 3-2. Weights of Cdh1fl/fl, Cdh1fl/+, and Cdh1+/+ mice.
(A,B) Cdh1fl/+ and Cdh1+/+ mice euthanized for cutaneous tumors, (C,D) Cdh1fl/+ and
Cdh1+/+ mice that died naturally.
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The majority of Cdh1fl/+ (Figure 3-2A) and Cdh1+/+ (Figure 3-2B) mice do not
undergo the significant weight loss that was observed in gastric cancer-bearing mice on a
Cdh1fl/fl background. Upon histologic analysis, only 2 of 11 Cdh1fl/+ mice and 1 of 15
Cdh1+/+ mice with subcutaneous tumors had histologically detectable stomach tumors.
The 7 Cdh1fl/+ mice and 6 Cdh1+/+ that died naturally lost weight prior to their death,
suggesting that they had developed gastric cancer (Figure 3-2C,D).
Cdh1fl/+ and Cdh1+/+ mice develop subcutaneous tumors

Figure 3-3. Subcutaneous tumors in Cdh1fl/+ and Cdh1+/+ mice.
(A) Gross image of a mouse with large tumors on its chest and pelvis, (B) Normal mouse
skin histology (http://ctrgenpath.net/), (C) 5x microscopic image of a subcutaneous
tumor, (D) 20x detail of compressed epidermis and dermis overlaying the subcutaneous
tumor, (E) 20x detail of thinned skeletal muscle underlying the subcutaneous tumor.
ACKPY mice with one (Cdh1fl/+) or two (Cdh1+/+) copies of wild-type Cdh1
developed cutaneous tumors throughout their bodies that necessitated euthanasia of the
animals prior to gastric cancer defined endpoints due to the inability of the mice to
ambulate (Figure 3-3A). Analysis of more Cdh1fl/fl mice revealed the occurrence of these
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tumors at a rate of approximately one in twenty. These cutaneous tumors arise in the
subcutaneous fat; they (Figure 3-3BC) were covered by epidermis and dermis (Figure
3-3D) and overlaid skeletal muscle (Figure 3-3E).

Initial characterization revealed

sarcomatoid histology.
Cdh1fl/+ stomach tumors are more focal and display sarcomatoid features
Although stomachs isolated from Cdh1fl/+ and Cdh1+/+ mice are enlarged and
hyperplastic (Figure 3-4C and A), the majority do not harbor tumors. When these mice
develop gastric tumors, they are more focal in nature (Figure 3-4D), unlike the
widespread tumors identified in Cdh1fl/fl stomachs (Figure 3-4B). This suggests that a
secondary event is occurring that is necessary for tumorigenesis to occur at these sites.
This event could be genetic, epigenetic, pathway upregulation, or other biological
processes that lead to carcinogenesis. Histologically, Cdh1fl/+ tumors are mixed-type
gastric cancer with sarcomatoid features.

Figure 3-4. Representative cross-sectional images of wild-type, Cdh1fl/fl, and Cdh1fl/+
stomachs.
(A) wild-type, (B) Cdh1fl/fl, (C) Cdh1fl/+ without tumor, and (D) Cdh1fl/+ with tumor
(scale bars = 5 mm).
Loss of E-cadherin Expression in Cdh1fl/+ Stomach Tumors
We hypothesized that the event occurring in these rare, focal, Cdh1fl/+ stomach
tumors might be loss of E-cadherin. E-cadherin expression was examined by
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immunofluorescent (IF) staining. E-cadherin is present in wild-type gastric epithelium
(Figure 3-5A). Similarly, E-cadherin expression is preserved in gastric tissue from
Cdh1fl/+ stomachs that lack tumors (Figure 3-5C) and in normal tissue of tumor bearing
Cdh1fl/+ mice (Figure 3-5D). However, in tumors of Cdh1fl/+ mice, E-cadherin expression
is absent or variable (Figure 3-5E). As expected, E-cadherin is absent in recombined cells
(YFP+) in Cdh1fl/fl stomachs, but present in adjacent normal (YFP-) tissue (Figure 3-5B).
Two primary cell lines were derived from independent Cdh1fl/fl stomachs and two
lines were derived from independent Cdh1fl/+ stomachs. Neither of the cell lines derived
from Cdh1fl/fl stomachs expressed E-cadherin by Western blot. However, only one of the
two Cdh1fl/+ gastric cancer cell lines expressed E-cadherin by Western blot (data not
shown). These data suggest that the hypothetical secondary event leading to tumor
formation in Cdh1fl/+ mice may be the loss of E-cadherin in some cases.

Figure 3-5. Representative immunofluorescent images of E-cadherin expression (white)
counter-stained with DAPI (blue) and for YFP (green).
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Cdh1 loss in a model of lung adenocarcinoma suppresses tumorigenesis
To determine whether E-cadherin loss accelerates tumorigenesis in all tissues, I
examined whether Cdh1 loss is necessary for lung cancer development. We administered
adenoviral Cre intratracheally to Cre negative Cdh1fl/fl (CKPY) and Cdh1fl/+ mice to
trigger oncogenic Kras activation, Trp53 loss with and without loss of Cdh1 in the lungs
(Johnson et al. 2001; Jackson et al. 2001; Jackson et al. 2005). Examination of lungs 12
weeks post infection demonstrated a decrease in overall tumor burden in Cdh1fl/fl mice
compared to Cdh1fl/+ mice (Figure 3-6, p=0.02). This is in marked contrast to the
dramatic increase in tumor burden observed in the stomach.

Figure 3-6. Cdh1fl/fl vs Cdh1fl/+ lung adenocarcinoma.
(A) Tumor to lung ratio for Cdh1fl/fl (n=5) vs Cdh1fl/+ (n=4), error bars represent standard
deviation. (B) Representative images of Cdh1fl/fl and Cdh1fl/+ lungs.
Subcutaneous tumors are more similar to sarcomas than gastric cancers
I wished to determine if these sarcomatoid subcutaneous tumors arising in
Cdh1fl/+ and Cdh1+/+ mice were primary sarcomas of the skin or metastatic lesions from
the stomach. Though most of the mice in which subcutaneous tumors arose lacked
detectable gastric tumors one could not rule out the possibility of small, unidentified
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gastric tumors that metastasized to the subcutaneous space. One could also not rule out
the possibility that these lesions were the result of off target Cre activation in the
subcutaneous space resulting in sarcoma formation. Microarray expression data from
glandular stomach tissue and subcutaneous metastasis tissue from four independent
Cdh1fl/+ mice was examined.
Initially, I analyzed the expression of the top 10 stomach enriched genes as
annotated by The Human Protein Atlas (Uhlén et al. 2015). Though only Gkn1 and
Muc5ac expression were statistically significant in their differential expression, there is a
clear trend toward lower expression of stomach specific genes in the subcutaneous
tumors.

Figure 3-7. Expression of stomach enriched genes in Cdh1fl/+ stomachs and subcutaneous
tumors.
Next, I compared two publically available microarray expression data sets from
the Gene Expression Omnibus (Edgar, Domrachev, and Lash 2002): GSE15459, 200
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primary gastric tumors from the Singapore patient cohort (Ooi et al. 2009), and
GSE21050, 310 soft tissue sarcomas from the French Sarcoma Group (Chibon et al.
2010). By comparing these data sets, I selected the top 25 genes that were more highly
expressed in the gastric cancers and the top 25 genes that were more highly expressed in
the sarcomas.
Using this set of 50 genes that differentiates between sarcomas and gastric
cancers, I performed hierarchical clustering analysis on the expression data from our
Cdh1fl/+ stomach and subcutaneous tumor microarrays. I found that the stomach samples
and the subcutaneous tumor samples formed distinct clusters. Further, the 25 genes more
highly expressed in gastric cancers were more highly expressed in the stomach samples
and the 25 genes more highly expressed in sarcomas were, for the most part, more highly
expressed in the subcutaneous tumors (Figure 3-8, Figure 3-9).
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Figure 3-8. Hierarchical clustering of Cdh1fl/+ stomach and subcutaneous tumor samples
based on 50 genes that differentiate between gastric cancer and sarcomas.
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Figure 3-9. Hierarchical clustering, for 50 genes that differentiate between gastric cancer
and sarcomas, of Cdh1fl/+ stomachs and subcutaneous tumors as well as Cdh1fl/fl stomachs
and metastases.
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iv. Discussion
E-cadherin as the gatekeeper to mutant Kras and Trp53 loss-driven gastric cancer
Though E-cadherin is well known in cancer biology as an “invasion suppressor
gene” (Birchmeier, Hülsken, and Behrens 1995; Pećina-Slaus 2003), here we
demonstrate its role as a suppressor of primary tumorigenesis. In gastric parietal cells,
despite the strong oncogenic stimulus of mutant Kras and Trp53 loss, E-cadherin
expression dramatically decreases tumorigenesis. From these data we can definitively say
that Cdh1 loss cooperates with oncogenic Kras expression and loss of Trp53 to promote
primary tumor formation. The observed loss of E-cadherin expression in the tumors that
arise in Cdh1fl/+ mice suggests that E-cadherin is a gatekeeper to tumorigenesis in gastric
parietal cells.
This function, however, appears to be somewhat specific to gastric parietal cells.
In our model of lung adenocarcinoma, loss of E-cadherin reduced primary tumor
formation. Of note, this is in contrast to the mutant C-raf driven model of lung cancer
where Cdh1 loss accelerated tumorigenesis (Table 3-2). However, this is a poor
comparison for two reasons: (1) the C-raf model had wild-type Trp53 and (2) oncogenic
C-raf only models activation of one of the many pathways downstream of Kras (as I will
discuss in Chapter 5). As discussed, the oncogenic Kras liver cancer model also displays
synergy between oncogenic Kras and loss of Cdh1 (Nakagawa et al. 2014). However,
loss of Trp53 paired with oncogenic Kras in the liver also accelerates tumor formation
and is not dependent on Cdh1 loss as we see here (O’Dell et al. 2012).
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This gatekeeper function of a tumor suppressor gene in the face of mutant Kras
and Trp53 loss is not without precedent. Recently, a similar phenomenon has been
observed with the adenomatous polyposis coli (Apc) tumor suppressor in colorectal
cancer (Dow et al. 2015). They showed that Apc knock-down in Lgr5+ colon cells led to
adenoma formation that was reversible with Apc restoration. They could drive
adenocarcinoma development with the addition of oncogenic Kras expression and Trp53
loss. However, even these adenocarcinomas regressed with restoration of Apc.
APC is an important member of the canonical Wnt pathway; though not directly
involved in the enzymatic modification of β-catenin, it is crucial in facilitating its
destruction and regulation through a variety of mechanisms (Mohammed et al. 2016).
Similarly, E-cadherin binds and sequesters β-catenin at adherens junctions. Presumably,
loss of either would lead to increased β-catenin signaling which may be crucial for
mutant Kras and Trp53 loss-driven oncogenesis in both gastric parietal cells and Lgr5+
colon stem cells.
Off target Cre activation results in subcutaneous sarcomas
The presence of subcutaneous tumors in the majority of Cdh1fl/+ and Cdh1+/+
mice as well as rarely in Cdh1fl/fl mice raises the question: are they independent tumors
arising in the subcutaneous space or metastases derived from gastric cancers arising in
these mice? These sarcomatoid lesions could be arising independently as a result of off
target Cre expression driving expression of oncogenic Kras and loss of Trp53 in a rare
skin cell population that expresses Atp4b for unknown reasons. It is well described that
oncogenic Kras and loss of Trp53 is sufficient to drive sarcomagenesis in the mouse with
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a latency of 56 to 117 days (median 79 days) (Kirsch et al. 2007). This latency is
strikingly similar to the age at which the subcutaneous tumors appear in our mice.
The lack of detectable gastric cancer in the majority of the Cdh1fl/+ and Cdh1+/+
would suggest that the subcutaneous tumors arise independent of gastric tumorigenesis.
However, we cannot rule out the possibility of small gastric lesions that we are not
detecting that are metastasizing. Further, the reported specificity of the Atp4b-Cre to
gastric parietal cells would argue against off-target activation. No specific data is
available on Cre specificity in the Atp4b-Cre strain I used (Syder et al. 2004), however
data is available on a similar strain produced by another group (Zengming Zhao et al.
2010). This group mated their strain to a conditional Smad4 allele and screened a panel of
tissues including skin for recombination. They only detected recombination in the
stomach. The Human Protein Atlas has immunohistochemical staining data of a variety
of tissues using two independent antibodies to ATP4B. They only detected expression in
gastric parietal cells and not the skin (“The Human Protein Atlas: ATP4B,” n.d.; Uhlén et
al. 2015).
However, this does not rule out a very rare cell population that was not
represented in their samples, expresses ATP4B at a level bellow their level of detection,
or a species-specific cell population in the skin of mice that expresses ATP4B. Further, a
hypothetical cell population may have sufficient activity at the transgenic Atp4b promoter
to drive Cre expression but insufficient activity at the endogenous Atp4b promoter (due
to other regulatory elements) to express ATP4B.
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Recent work has shown that the majority of stringently tested targeted Cre strains
have unreported off-target activities (Heffner et al. 2012). In addition, the gene
expression analysis I performed comparing the stomachs of Cdh1fl/+ mice to their
subcutaneous tumors strongly suggests these tumors have an expression profile more
consistent with sarcomas than with gastric-derived metastases. The subcutaneous tumors
can be differentiated from the stomachs based on genes specific to sarcomas versus
gastric cancers (Figure 3-8) and stomach-enriched genes (Figure 3-7).
Finally, assuming the Cdh1fl/+ sub-cutaneous tumors are sarcomas arising from
rare Cre expression in a mesenchymal skin cell, one would expect these tumors to arise in
Cdh1fl/fl mice as well given that they use the same Atp4b-Cre transgene. In fact,
subcutaneous tumors are rarely observed in the Cdh1fl/fl mice at a rate of about 1 in 20. As
the subcutaneous tumors typically arise at approximately 3 months of age in the Cdh1fl/+
mice, one would only expect them to be seen in Cdh1fl/fl mice that live to this age.
However, median survival of Cdh1fl/fl mice is 76.5 days, to young to see subcutaneous
tumors arise in the majority of these mice.
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CHAPTER 4 E-CADHERIN LOSS UPREGULATES Β-CATENIN SIGNALING
IN THE ACKPY MOUSE MODEL OF GASTRIC CANCER
i. Abstract
E-cadherin has been shown to bind and inhibit the oncogenic function of βcatenin (Gottardi, Wong, and Gumbiner 2001). Several groups have previously
demonstrated that loss or mutation of E-cadherin alone does not increase β-catenin
signaling in gastric and pancreatic cancer cells (Caca et al. 1999), breast cancer cells (van
de Wetering et al. 2001) or β-cell tumors (Herzig et al. 2007) . However, in our model of
gastric cancer, E-cadherin loss drives β-catenin activation and inhibition of β-catenin
signaling prolonged survival of our ACKPY mice. Given these conflicting results, we
must consider the context of this increase in β-catenin signaling in our model. Many
studies have demonstrated cross-activation of canonical WNT signaling by the receptor
tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) pathway (Zeller et
al. 2013). Taken together, these data suggest crosstalk between oncogenic Kras and loss
of E-cadherin in our model, wherein oncogenic Kras primes the system by inactivating
the β-catenin destruction machinery (Lemieux et al. 2015) and loss of E-cadherin releases
β-catenin from sequestration.
ii. Introduction
Canonical WNT signaling, sometimes referred to as the “β-catenin dependent”
pathway, results in β-catenin translocation to the nucleus and upregulation of target
genes. The amount of free β-catenin is tightly regulated in the cell by phosphorylation,
ubiquitination, and proteasomal degradation. In the absence of WNT ligands, free β52

catenin is bound and phosphorylated by a complex consisting of Axin, Adenomatous
polyposis coli (APC), Casein kinase 1 alpha (CK1α), and glycogen synthase kinase 3β
(GSK3β). Phosphorylated β-catenin is recognized and ubiquitinated by the E3 ligase βtransducin repeat-containing protein (β-TrCP) targeting β-catenin for proteasomal
degradation (Figure 4-1A). When WNT ligands are present, they bind to the
Frizzled(FZ)/Low-density lipoprotein receptor-related protein 5/6 (LRP5/6) receptor
complex, leading to dissociation of the Axin/APC/CK1α/GSK3β destruction complex.
This is achieved by the binding of Dishevelled (Dvl) to the ligand-bound Fz/LRP5/6
receptor complex, which leads to the phosphorylation of LRP5/6 and binding of Axin to
the receptor complex. Dissociation of the destruction complex prevents phosphorylation
of β-catenin, results in its accumulation, and subsequent translocation to the nucleus. In
the nucleus, it binds the T-cell factor (TCF)/lymphoid enhancing factor (LEF)
transcription factor complex, displacing negative regulator Groucho, and activating
transcription of target genes (Figure 4-1B) (Chiurillo 2015).
Canonical WNT signaling has long been implicated in the development of gastric
cancer. Many studies have shown increased expression or activating mutation of positive
WNT regulators and decreased expression or inactivating mutation of WNT repressors in
gastric cancer samples and cell lines (Chiurillo 2015). Several studies have demonstrated
that H. pylori can also upregulate canonical WNT signaling (Song et al. 2015). Relevant
to the model I present here, E-cadherin has long been known to bind cytoplasmic βcatenin and suppress its oncogenic activity by sequestering it in the cadherin-catenin
complex (Gottardi, Wong, and Gumbiner 2001). It has been suggested, but not shown,
53

that reciprocal regulation occurs; that loss of E-cadherin can lead to increased oncogenic
transformation through release of free β-catenin (Gottardi, Wong, and Gumbiner 2001;
Liu et al. 2014; Chiurillo 2015). Here I present the first direct evidence demonstrating
that loss of E-cadherin, at least in the context of oncogenic Kras and loss of p53 in gastric
parietal cells, is sufficient to increase β-catenin signaling.

A

B
Figure 4-1. Canonical WNT pathway.
(A) WNT ligand absent. (B) WNT ligand present)

Results
Microarray reveals upregulation of TCF/LEF targets with E-cadherin loss
To identify differential gene expression in our model of gastric cancer, I
performed a microarray on glandular stomach tissue from four independent Cdh1fl/fl and
Cdh1fl/+ mice. Principal components analysis revealed two clusters: one that contained 3
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of the Cdh1fl/+ stomachs and a second that contained all 4 of the Cdh1fl/fl stomachs. One
of the Cdh1fl/+ stomachs did not fall distinctly within either of these groups but was closer
to the Cdh1fl/fl stomachs (Figure 4-2A). Unsupervised hierarchical clustering analysis
indicates that the single outlier Cdh1fl/+ stomach sample clustered more closely to Cdh1fl/fl
stomachs rather than Cdh1fl/+ stomachs (Figure 4-2B). One interpretation of these data
suggests that this Cdh1fl/+ outlier contained a rare Cdh1fl/+ tumor and thus clusters closer
to the Cdh1fl/fl tumor containing stomachs than the other, tumor free, Cdh1fl/+ stomachs.
This data correlates with the 1 in 4 frequency of stomach tumors observed in Cdh1fl/+
mice. Microarray data from the Cdh1fl/+ outlier was removed from future analysis due to
the likely presence of a stomach tumor.

Figure 4-2. Principal component analysis and unsupervised hierarchical clustering
analysis of microarray data from Cdh1fl/fl and Cdh1fl/+ stomachs.
To determine which pathways were differentially regulated between the two
genotypes, I performed gene set overlap analysis (Subramanian et al. 2005) on genes
upregulated in the Cdh1fl/fl stomachs versus Cdh1fl/+ stomachs and a publicly available
data set of transcription factor target gene sets. The first hit was a set of genes containing
a LEF1 binding site in their promoters, and the sixth was a set of genes containing the
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TCF3 binding site (Table 4-1). Further, when genes upregulated in Cdh1fl/fl versus
Cdh1fl/+ stomachs were compared to oncogenic signature gene sets, the results contained
several genes sets whose upregulation resulted from expression of LEF1, WNT1, and
CTNNB1 (Table 4-1). All these data are consistent with an up-regulation of β-catenin
target genes.
Name

Description

FDR q-value

Transcription Factor Target Gene Sets
CTTTGT_V$LEF1_Q2

Genes with promoter regions containing the LEF1 motif

3.27 e-87

CAGGTG_V$E12_Q6

Genes with promoter regions containing the TCF3 motif

1.44 e-58

Oncogenic Signature Gene Sets
LEF1_UP.V1_UP

Upregulated in DLD1 cells over-expressing LEF1

2.86 e

WNT_UP.V1_UP

Upregulated in C57MG cells over-expressing WNT1

1.42 e

BCAT.100_UP.V1_UP

Upregulated in HEK293 cells expressing active CTNNB1

3.83 e

-19
-8
-8

Table 4-1. Selected results from Gene Set Overlap Analysis comparing genes
overexpressed in Cdh1fl/fl vs. Cdh1fl/+ to transcription factor target gene sets and
oncogenic signature gene sets.
Validation of β-catenin target gene regulation by E-cadherin
To validate the microarray data, I analyzed RNA isolated from stomachs of other
Cdh1fl/fl and Cdh1fl/+ mice for expression of several canonical WNT/β-catenin target
genes: MYC (He et al. 1998), CCND1 (McCormick and Tetsu 1999; Shtutman et al.
1999), AXIN2 (Yan et al. 2001; Lustig et al. 2002; Jho et al. 2002), LEF1 (Hovanes et al.
2001; Filali et al. 2002; T. W.-H. Li et al. 2006), CD44 (Wielenga et al. 1999; Zeilstra et
al. 2008), MMP7 (Crawford et al. 1999; Brabletz et al. 1999). All genes were
significantly upregulated in Cdh1fl/fl compared to Cdh1fl/+ stomach tissues.
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Figure 4-3. qPCR validated upregulation of WNT/β-catenin targets in Cdh1fl/fl over
Cdh1fl/+ stomachs.
Loss of membranous β-catenin in Cdh1fl/fl and Cdh1fl/+ tumors mirrors loss of E-cadherin
β-catenin is normally sequestered at the plasma membrane by E-cadherin. To test
if loss of E-cadherin alters the subcellular localization of β-catenin, I co-immunostained
Cdh1fl/fl and Cdh1fl/+ stomachs with and without tumors for E-cadherin, β-catenin, and
YFP. As expected, a wild-type control stomach lacked YFP but expressed E-cadherin and
β-catenin that were localized to the plasma membrane (Figure 4-4A, white arrows).
Conversely, Cdh1fl/fl stomachs showed loss of expression of E-cadherin and β-catenin in
YFP+ tumors (Figure 4-4B, yellow arrows), but expression patterns were normal in YFPareas (Figure 4-4B, white arrows).
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Figure 4-4. Representative images showing loss of membranous β-catenin in Cdh1fl/fl and
Cdh1fl/+ tumors.
(White arrows) Retained E-cadherin and β-catenin in YFP negative areas. (Yellow
arrows) Lost E-cadherin and β-catenin in YFP positive tumor areas. (Orange arrows)
Retained E-cadherin and β-catenin in YFP positive non-tumor areas.
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The Cdh1fl/+ stomach without a tumor (Figure 4-4C) and the normal area of a Cdh1fl/+
stomach with a tumor (Figure 4-4D) retained expression of E-cadherin and β-catenin
throughout (Figure 4-4, orange arrows). In contrast to the benign regions, the tumor area
of the Cdh1fl/+ stomach displayed loss of membranous expression of E-cadherin and βcatenin (Figure 4-4E, yellow arrows).
Inhibition of β-catenin/TCF signaling increases survival of ACKPY mice
To test the necessity of β-catenin signaling in our ACKPY gastric cancer mouse
model, I treated mice with the β-catenin/TCF complex inhibitor PKF118-310. Though the
effect size is small, mice treated with the inhibitor had a statistically significant (p=0.04)
6-day increase in median survival (78 days) over vehicle treated mice (72 days).

Figure 4-5. Kaplan-Meier curve showing increased survival with PKF118-310 treatment.
Beginning at 4-weeks of age, mice were injected 3x per week with 1 mg/kg PKF118-310
(red, n=8) or a volumetrically equivalent does of 0.1% DMSO vehicle (black, n=13)
intra-peritoneally.
Activation of β-catenin with LiCl did not promote tumorigenesis in Cdh1fl/+ mice
To determine if β-catenin activation was sufficient to drive tumorigenesis in
Cdh1fl/+ mice, I treated them with the GSK3β inhibitor lithium chloride (LiCl). GSK3β is
a key component of the degradation complex that phosphorylates β-catenin and targets it
for ubiquitination and proteasomal degradation. Inhibition or loss of GSK3β leads to
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increased free β-catenin that can translocate to the nucleus, bind TCF/LEF, and transcribe
targets. My preliminary data suggest no difference in stomach tumor incidence between
LiCl treated Cdh1fl/+ mice and vehicle treated Cdh1fl/+ mice (data not shown). However,
interpretation of these data is limited as we were not able to confirm efficacy of the
inhibition by assaying for destruction complex activity.
iii. Discussion
Though it has long been hypothesized that E-cadherin loss would lead to
upregulation of β-catenin signaling, several studies have shown that this may not be the
case. For example, cancer cell lines with deletion (Caca et al. 1999) or mutation (van de
Wetering et al. 2001) of E-cadherin did not show constitutive β-catenin/TCF/LEF
signaling. Further, in the Rip1Tag2 model of β-cell carcinogenesis, E-cadherin loss is
rate-limiting. However, it has been shown that this loss does not upregulate β-catenin
target genes and cannot be phenocopied by forced activation of TCF or β-catenin
transcriptional activity (Herzig et al. 2007). Taken together, these data suggest that
though loss of E-cadherin may release β-catenin from sequestration, the nuclear activity
is still inhibited by a functional destruction complex (Jeanes, Gottardi, and Yap 2008).
Here we show that loss of E-cadherin is sufficient to drive increased βcatenin/TCF/LEF signaling in our model and that this signaling is important to the
survival phenotype. However, the status of the β-catenin destruction complex is not
known. Given the data suggesting E-cadherin loss alone is not sufficient to drive βcatenin signaling, we must consider the hypothesis that other manipulation in our model
may be affecting the destruction complex.
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In

fact,

many

studies

have

shown

significant

crosstalk

between

the

RTK/Ras/mitogen-activated protein kinase (MAPK) pathway and canonical WNT
signaling (Zeller et al. 2013). For example, in intestinal tumor formation, APC and Kras
mutation are synergistic not only in promoting tumor formation but also in the activation
of WNT signaling (Janssen et al. 2006). One potential mechanism elucidated in colorectal
cancer cell lines reveals that oncogenic Kras, functioning through the MAPK pathway,
can activate canonical WNT signaling by phosphorylation of LRP6 (Lemieux et al.
2015). Additionally, in their investigation of the Trp53/Cdh1 double conditional model,
Shimada et al did not observe any expression of β-catenin in their tumors and concluded
that β-catenin signaling was not involved in the development of diffuse gastric cancer in
their model (2012).
Taken together, these data suggest that our β-catenin signaling phenotype is a
synthetic phenotype resulting from both the loss of E-cadherin and expression of
oncogenic Kras in our model: loss of E-cadherin releases β-catenin from sequestration
and oncogenic Kras inhibiting the destruction complex. Further, it may suggest a reason
why we do not see increased tumorigenesis in the LiCl treatment group. This treatment
may be redundant in targeting the destruction complex that may already be impaired by
oncogenic Kras.
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CHAPTER 5 LOSS OF E-CADHERIN CORRELATES WITH UPREGULATION
OF ONCOGENIC KRAS TARGET GENES IN THE ACKPY MOUSE MODEL
OF GASTRIC CANCER
i. Abstract
Ras oncogenes directly regulate four core signaling pathways that influence
nearly every hallmark of cancer (Hanahan and Weinberg 2000; Hanahan et al. 2011): the
mitogen

activated

kinase

(MAPK)

pathway,

the

phosphatidylinositol-3-kinase

(PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, the Ras-like GTPase
guanine nucleotide exchange factor (Ral-GEFs) pathway, and the phospholipase C
isoform ε (PLCε) pathway (Pylayeva-Gupta, Grabocka, and Bar-Sagi 2011). Microarray
data comparing gene expression in stomachs harvested from Cdh1fl/fl vs. Cdh1fl/+ mice
correlates E-cadherin loss with the upregulation of oncogenic Kras signaling in our
model. Gene sets regulated by MAPK activation were among those over-represented in
our microarray analysis. However, examination of extracellular signal-related kinase
(ERK) phosphorylation revealed that E-cadherin does not regulate MAPK activity in our
model. The upregulation of oncogenic Kras target genes that result from the loss of Ecadherin may alternatively be explained by E-cadherin regulation of other Kras effector
pathways. In fact, E-cadherin loss correlated with upregulation of gene sets driven by
activation of each of the other effector pathways.
ii. Introduction
The Ras family of oncogenes has been extensively studied since its discovery in
the early 1980s (Tsuchida et al. 2016). They have been implicated in the regulation of
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nearly all of the hallmarks of cancer as outlined by Hanahan and Weinberg (Hanahan and
Weinberg 2000; Hanahan et al. 2011; Pylayeva-Gupta, Grabocka, and Bar-Sagi 2011).
The four core pathways they directly regulate have been known since the early 2000s
(Downward 2003). While their reach seems endless, new downstream effectors are still
being discovered (F. Zhang and Cheong 2016).
The first Ras effector discovered was the Raf/mitogen activated protein kinase
(MAPK) pathway. Activated Ras binds and activates Raf, a kinase complex, which then
activates MAPK/ERK Kinase (MEK) by phosphorylating it. MEK phosphorylates and
activates the extracellular signal-related kinase (ERK), also known as MAPK. ERK
phosphorylates a myriad of both cytoplasmic and nuclear targets, many of which are
transcription factors (Mendoza, Er, and Blenis 2011).
Ras also activates the lipid kinase phosphatidylinositol-3-kinase (PI3K),
generating the signaling molecule phosphatidyl inositol 3,4,5 tri-phosphate (PIP3). PIP3
recruits the kinase Akt to the plasma membrane where another target of PIP3, 3phosphoinositide-dependent kinase 1 (PDK1), and the mammalian target of rapamycin
(mTOR) complex 2 (mTORC2) activate it by phosphorylation. Akt has many targets that
regulate a variety of pathways; most notable is its inhibition of the tuberous sclerosis
complex genes (TSC1/2) that inhibit the GTPase Ras homolog enriched in brain (RHEB)
that activates mTORC1. As such, Akt disinhibits RHEB via inhibition of TSC1/2 leading
to activation of mTORC1, a master regulator of cell survival, division, and metabolism
(Mendoza, Er, and Blenis 2011).
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Ras also activates the Ras-like GTPases (Rals) via their guanine nucleotide
exchange factors (GEFs). Like Ras proteins, the Rals interact with a variety of effectors
to influence exocytosis, endocytosis, actin organization, second messenger production,
and transcription factor activity. One such effector pathway results in NF-κB activation.
RalB promotes the association of Sec5 with TANK-binding kinase (TBK1), which
increases its activity as an inhibitor of κB (IκB) kinase (IKK), thereby relieving
inhibition of NF-κB (Neel et al. 2011).
The fourth canonical target of Ras is phospholipase C (PLC) isoform ε, which
increases its activity. PLC enzymes generate two important second messengers:
diacylglycerol (DAG), which activates phosphokinase C (PKC), and inositol 1,4,5trisphosphate (IP3), which leads to an increase in intracellular calcium by release from
intracellular stores and influx through cell membrane channels. Both of these pathways
regulate a variety of pathways. As with the RalGEF pathway, the PLCε has also been
shown to activate NF-κB (R.-Y. Zhang et al. 2016). Additionally, increased intracellular
calcium activates calcineurin, which dephosphorylates the transcription factor nuclear
factor of activated T cells (NFAT), exposing its nuclear localization signal and inducing
translocation to the nucleus, thereby activating NFAT (Mognol et al. 2016).
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Figure 5-1. Main downstream effector pathways of the Ras family of oncogenes
(Downward 2003; F. Zhang and Cheong 2016).
iii. Results
Microarray analysis correlates loss of E-cadherin with upregulation of oncogenic Kras
signaling and increased expression of MAPK target genes
The microarray gene set overlap analysis (GSOA) data, described in Chapter 3,
also revealed that RTK/Kras/MAPK driven gene sets were over-represented in our
Cdh1fl/fl versus Cdh1fl/+ stomach gene set. When comparing our gene set to the collection
of cancer hallmark gene sets, the second most significant hit was one for “genes upregulated by Kras activation.” Further, significant overlap was found between our gene
set and RTK/Kras/MAPK regulated gene sets (oncogenic signature gene sets), including
9 resulting from the over-expression of oncogenic KRAS and 4 from activation of
RTK/MAPK components (Table 5-1). Given that both Cdh1fl/fl and Cdh1fl/+ stomachs
express oncogenic Kras, these data suggest that E-cadherin presence or loss may regulate
the activity of oncogenic Kras in our model.
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Name

Description

FDR q-value

Cancer Hallmark Gene Sets
HALLMARK_KRAS_SIGNALING_UP

Genes up-regulated by KRAS activation.

3.36E-61

Up-regulated in MCF-7 cells engineered to
express ligand-activatable EGFR
Up-regulated in MCF-7 cells stably overexpressing constitutively active MAP2K1
Up-regulated in MCF-7 cells stably overexpressing constitutively active RAF1
Up-regulated in four lineages of epithelial
cell lines over-expressing oncogenic KRAS
Up-regulated in MCF-7 cells engineered to
express ligand-activatable ERBB2
Up-regulated in epithelial lung cancer cell
lines over-expressing oncogenic KRAS
Up-regulated in epithelial lung and breast
cancer cell lines over-expressing oncogenic
KRAS
Up-regulated in epithelial lung and breast
cancer cell lines over-expressing oncogenic
KRAS
Up-regulated in epithelial breast cancer cell
lines over-expressing oncogenic KRAS
Up-regulated in epithelial lung cancer cell
lines over-expressing oncogenic KRAS
Up-regulated in four lineages of epithelial
cell lines over-expressing oncogenic KRAS
Up-regulated in epithelial prostate cancer
cell lines over-expressing oncogenic KRAS
Up-regulated in four lineages of epithelial
cell lines over-expressing oncogenic KRAS

7.54E-27

Oncogenic Signature
EGFR_UP.V1_UP
MEK_UP.V1_UP
RAF_UP.V1_UP
KRAS.600_UP.V1_UP
ERB2_UP.V1_UP
KRAS.DF.V1_UP
KRAS.600.LUNG.BREAST_UP.V1_UP

KRAS.LUNG.BREAST_UP.V1_UP

KRAS.BREAST_UP.V1_UP
KRAS.LUNG_UP.V1_UP
KRAS.300_UP.V1_UP
KRAS.PROSTATE_UP.V1_UP
KRAS.50_UP.V1_UP

1.30E-25
1.30E-25
1.47E-19
9.62E-19
9.39E-18
2.68E-17

2.55E-15

4.49E-11
1.34E-10
8.06E-09
2.75E-08
2.78E-07

Table 5-1. Gene set overlap analysis comparing cancer hallmark gene sets and oncogenic
signature gene sets to genes up-regulated in Cdh1fl/fl versus Cdh1fl/+ stomachs.
E-cadherin does not attenuate MAPK activity
ERK, the downstream effector of the MAPK pathway, is activated by
phosphorylation. To assess the effect of E-cadherin on the MAPK pathway activity
downstream of oncogenic Kras, stomach tissue from Cdh1fl/fl and Cdh1fl/+ mice was
stained by immunofluorescence (IF) for phospho-ERK (pERK) and yellow fluorescence
66

protein (YFP) expression. Preliminary data comparing two stomach samples of each
genotype suggested a considerable increase in pERK in the Cdh1fl/fl stomachs over the
Cdh1fl/+ stomachs (Figure 5-2A).
For quantitative analysis, I examined two larger cohorts of mice. One cohort,
referred to as the terminal cohort, was composed of Cdh1fl/fl mice that had reached the
humane survival endpoint (20% loss of body weight) and Cdh1fl/+ mice that had reached
the humane endpoint for their subcutaneous tumors (≥ 2 cm3). A second cohort was
composed of age-matched Cdh1fl/fl and Cdh1fl/+ mice euthanized between 9 and 10 weeks
of age. IF staining of the terminal cohort revealed a trend towards increased pERK in
Cdh1fl/fl stomachs over Cdh1fl/+ stomachs, but this difference was not statistically
significant (p = 0.15). However, IF staining of the age-matched cohort exhibited no such
trend (Figure 5-2B).
To further analyze pERK expression in tissue sections, I performed
immunohistochemical (IHC) staining on the same cohorts. In contrast to the IF staining,
IHC staining of the terminal cohort indicated a trend toward increased expression of
pERK in Cdh1fl/+ stomachs over Cdh1fl/fl stomachs (p=0.23). In the age-matched cohort,
this finding was a statistically significant increase (p=0.01). Additionally, analysis of the
combination of these two cohorts revealed a statistically significant increase in pERK in
Cdh1fl/+ stomachs over Cdh1fl/fl stomachs (p=0.01, Figure 5-2C).
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Figure 5-2. Results from pERK staining experiments in Cdh1fl/fl and Cdh1fl/+ stomachs.
(A) Initial immunofluorescence staining for pERK (red) and YFP (green) in Cdh1fl/fl and
Cdh1fl/+ stomachs. Counterstained with DAPI (blue), 63x.
(B) Quantitative analysis of immunofluorescence staining for pERK+ and YFP+ overlap
area (relative to total YFP+ area) in two Cdh1fl/fl vs. Cdh1fl/+ stomach cohorts.
(C) Quantitative analysis of immunohistochemical staining for pERK+ (relative to total
stomach area) in two Cdh1fl/fl vs. Cdh1fl/+ stomach cohorts, separate and combined.
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Microarray analysis correlates loss of E-cadherin with upregulation of oncogenic Kras
MAPK-independent effector pathways
Name

Description

FDR
q-value

PI3K/AKT/mTOR Gene Sets
HALLMARK_MTORC1_SIGNALING

Up-regulated through activation of mTORC1
complex.
Up-regulated by activation of the
PI3K/AKT/mTOR pathway.
Down-regulated by everolimus (mTOR inhibitor) in
prostate tissue.
Up-regulated in HCT116 cells upon knockdown of
PTEN
Down-regulated by everolimus (mTOR inhibitor) in
mouse prostate tissue transgenically expressing
human AKT1

1.76E-08

HALLMARK_TNFA_SIGNALING_VIA_NFKB

Regulated by NF-kB in response to TNF

5.52E-45

V$NFKAPPAB_01

Genes with promoter regions containing the NFKB
binding site
Genes with promoter regions containing the RELA
binding site
Immune or inflammatory genes induced by NF-KB
in primary keratinocytes and fibroblasts.
Genes down-regulated in HEK293 cells upon
knockdown of RELA

1.57E-17

Genes with promoter regions containing the NFAT
binding site
Genes with promoter regions containing the NFAT
binding site

1.47E-69

HALLMARK_PI3K_AKT_MTOR_SIGNALING
MTOR_UP.V1_DN
PTEN_DN.V2_UP
AKT_UP_MTOR_DN.V1_DN

4.54E-02
1.31E-12
2.98E-11
1.76E-10

NF-κB Gene Sets

V$NFKAPPAB65_01
HINATA_NFKB_IMMU_INF
RELA_DN.V1_DN

1.42E-14
6.26E-07
2.21E-06

NFAT Gene Sets
TGGAAA_V$NFAT_Q4_01
V$NFAT_Q6

1.17E-18

Table 5-2. Gene set overlap analysis results for downstream KRAS pathways that are
MAPK-independent.
Further review of the microarray GSOA revealed MAPK-independent gene sets
downstream of oncogenic KRAS also overlapped with our Cdh1fl/fl over Cdh1fl/+ stomach
gene set. Using GSOA, our gene set overlapped with two publicly available cancer
hallmarks gene sets upregulated by activation of the PI3K/AKT/mTOR pathway.
Comparison of our gene sets to oncogenic signature gene sets demonstrated overlap with
three sets of genes also upregulated by activation of the PI3K/AKT/mTOR pathway
(Table 5-2, white). Gene sets upregulated by NF-κB were also over-represented in
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comparison to cancer hallmarks gene sets (1 gene set), transcription factor target gene
sets (2 gene sets), and oncogenic signature gene sets (2 gene sets) (Table 5-2, light gray).
There was also overlap with two transcription factor target gene sets for NFAT (Table
5-2, dark gray).
iv. Discussion
Investigating E-cadherin regulation of MAPK
The suggestion that E-cadherin might negatively regulate the MAPK pathway
downstream of oncogenic Kras in our model was intriguing. While crosstalk between Ecadherin and receptor tyrosine kinases (RTKs) has been suggested (Andl and Rustgi
2005) only two papers demonstrate E-cadherin-dependent down-regulation of MAPK
(Laprise et al. 2004; Soto et al. 2008). Crosstalk between the canonical WNT and
RTK/KRAS/MAPK pathways is well-described (Zeller et al. 2013), but only one study
has implicated β-catenin signaling in the regulation of the pathway downstream of RTKs
(Zeller et al. 2012). Prior to our semi-quantitative pERK staining data that suggest that
this initial observation may not be true, we began to consider several pathways that could
have potentially been at play.
First, E-cadherin has been shown to bind and activate the PI3K-p85 regulatory
subunit, resulting in activation of Akt (De Santis et al. 2009). This E-cadherin regulation
of the PI3K/Akt pathway has been shown to inhibit MEK/ERK activity (Laprise et al.
2004). We hypothesized that E-cadherin in Cdh1fl/+ stomachs might lead to increased
AKT activity that might explain the inhibition of pERK in these mice. As such, I
examined Cdh1fl/fl and Cdh1fl/+ stomach tissue for the active form of AKT (pAKT70

Ser473) by IF. In a pilot experiment, I did not observe pAKT expression in either cohort
(data not shown).
Second, E-cadherin and β-catenin have been shown to influence the expression of
several negative regulators of MAPKs (MAPK phosphatases, MKPs): dual specific
phosphatase 6 and 14 (DUSP6/14) (Zeller et al. 2012), and sprouty homolog 2 (SPRY2)
(Barbáchano et al. 2010). We hypothesized that E-cadherin expression or the lack of βcatenin signaling in Cdh1fl/+ stomachs could lead to an increase in expression of a MAPK
phosphatase that could cause a decrease in the phosphorylated state of ERK in these
stomachs. Due to the large number of MKPs and the fact that the reported regulation by
E-cadherin/β-catenin was at the transcriptional level, we began our examination of MKP
expression in a panel of Cdh1fl/fl and Cdh1fl/+ stomach RNAs by qPCR. I did not observe
increased expression in the Cdh1fl/+ RNAs of any of the 10 MAPK regulatory DUSPs
(Kidger and Keyse 2016), 4 SPRYs, or 3 SPREDs (sprouty related EVH1 domain
containing) (data not shown).
Third, in the context of a mouse model of lung carcinogenesis, it is has been
shown that BrafV600E can drive oncogene-induced senescence (OIS) that is rescued by
canonical WNT driven cMyc expression (Juan et al. 2014). I hypothesized that KrasG12D
in Cdh1fl/+ stomachs might similarly drive OIS that would result in an inhibition of
MAPK activity. In Cdh1fl/fl stomachs, this could be rescued by cMyc upregulation as a
result of E-cadherin loss-driven β-catenin signaling. This mechanism is not possible, as
OIS is dependent on p53 activity and Trp53 is knocked out in our model.
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Fourth, E-cadherin is known to inhibit p120-Rac1 activity. This inhibition has
been shown to be necessary for Raf/MEK activation (Soto et al. 2008). I hypothesized
that loss of E-cadherin in Cdh1fl/fl stomachs led to loss of inhibition of p120-Rac and
ultimate disinhibition of Raf/MEK (re: MAPK) activity. Unfortunately, there is no way to
assess Rac1 activity in tissue sections.
E-cadherin does not down-regulate MAPK activity
Ultimately, the initial observation of a decrease in pERK expression in Cdh1fl/+
stomachs compared to Cdh1fl/fl stomachs was not borne out upon examination of larger
cohorts. By IF, there was no significant difference in pERK expression between the
genotypes. However, by IHC there was a contrasting increase in pERK staining in
Cdh1fl/+ stomachs compared to Cdh1fl/fl stomachs (or decrease in pERK staining in
Cdh1fl/fl stomachs compared to Cdh1fl/+ stomachs). This difference is likely due to the
lack of co-staining and subsequent controlling for YFP in the IHC analysis.
For IF analysis, I measured the area of pERK and YFP co-expression divided by
total YFP+ area per microscopic field (averaged over multiple fields and tissue planes).
This controlled for the relative abundance of Cre-transformed cells of interest by
excluding cells untransformed cells and acellular areas. I analyzed the IHC data by
measuring the total pERK stained area per slide divided by the total tissue area per slide
(each slide containing several tissue planes). This IHC analysis did not account for the
area of the tissue that was Cre transformed (i.e. YFP+). This could be corrected by
staining for YFP on a serial section and dividing the pERK stained area per slide by the
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YFP+ area per slide. Qualitatively, I did observe greater YFP positivity throughout
Cdh1fl/+ stomachs compared to Cdh1fl/fl stomachs that might explain this finding.
MAPK-independent Kras pathways may drive Kras signature in microarray data
Due to my initial observation of a decrease in pERK expression in Cdh1fl/+
stomachs compared to Cdh1fl/fl stomach, I focused my work and analysis on the role of
the MAPK pathway. However, revisiting the initial GSOA data suggests an alternative
interpretation of the apparent effect of E-cadherin on Kras-regulated genes. The GSOA
results not only suggested regulation of the MAPK pathway downstream of Kras, but also
of the PI3K/Akt/mTOR, NF-κB, and PLCε/PKC/Ca2+ (i.e. NFAT) pathways. Our
staining data suggest that E-cadherin does not negatively regulate the Ras/MAPK axis,
but it may regulate one or more of these pathways. If yes, that regulation could explain
the strong Kras-driven gene signature present in our Cdh1fl/fl over Cdh1fl/+ stomach gene
set. Further experiments are necessary to confirm or refute E-cadherin regulation of these
pathways, I will discuss that further in the following conclusions and future directions
chapter.
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CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS
i. ACKPY Metastatic Model of Gastric Cancer
Conclusions
The ACKPY mouse model is a promising new model of metastatic gastric cancer.
By combining genetic lesions that represent common pathways mutated in gastric cancer,
we have generated a clinically relevant model of gastric cancer that mimics both the
etiology of disease and the observed disease progression. Unlike most mouse models of
gastric cancer, ours metastasizes widely, mirroring the common presentation of patients
in the clinic with advanced disease. In contrast to other mouse models of gastric cancer,
ours progresses quickly, allowing for timely analyses. I demonstrated the potential
preclinical utility of our model by treating our mice with a MEK inhibitor. However, this
model, as all models, is not without limitation and caveats.
First, though we set out to generate a model of diffuse gastric cancer, the
phenotype we observe is that of mixed-type, containing both intestinal-type and diffusetype lesions. This phenotype may be a disadvantage of the model, as it is the least
common form of gastric cancer (Polkowski et al. 2016). Yet, this is the first mouse model
of mixed-type gastric cancer and is therefore the only model available to study this hybrid
form of the disease. Furthermore, it may have implications for understanding the
differences, similarities, and distinct etiologies of intestinal- and diffuse-type cancers, as
both types of lesions arise from the same genetic modifications in our model. The
presence of both intestinal- and diffuse-type lesions in one model may also be an
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advantage as treatments could be assessed as to their effect on each type of lesion in the
same model.
The above presumes the prevailing narrative that intestinal- and diffuse-type
gastric cancers represent distinct diseases with differing etiologies. Intestinal-type gastric
cancer has traditionally been associated with the Correa pathway and is thought to be
more related to environmental effects (Correa 1992; Muñoz and Asvall 1971). The
histologic progression to diffuse-type is less well understood (Fox and Wang 2007), and
the etiology is less associated with environmental effects (Muñoz and Asvall 1971) but is
known to be related to loss of expression of E-cadherin (Graziano, Humar, and Guilford
2003). In these discussions the presence of mixed-type gastric cancer is always
conveniently absent.
However, H. pylori infection is strongly associated with both forms of the disease
(Fox and Wang 2007). Further, the recent molecular classification systems developed by
the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) do not
categorize intestinal- and diffuse-type disease perfectly within subsets. Though both
groups find that their classification of Laurén types is statistically significant, a thorough
review of the data reveals a more complex picture. Additionally, mixed-type gastric
cancer is quite evenly distributed among subtypes (Table 6-1 & Table 6-2) (Bass et al.
2014; Cristescu et al. 2015). These data might suggest that our current classification
scheme, based solely on histologic appearance as described by Laurén in the 1960s, does
not actually define distinct diseases.
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Diffuse
Intestinal
Mixed
Not Specified

Total
n
%
69 23.4%
196 66.4%
19
6.4%
11
3.7%

n
5
15
3
3

TCGA Classification
EBV
MSI
GS
%
n
%
n
%
19.2%
6
9.4% 40 69.0%
57.7% 48 75.0% 15 25.9%
11.5%
3
4.7%
3
5.2%
11.5%
7 10.9%
0
0.0%

CIN
n
18
118
10
1

%
12.2%
80.3%
6.8%
0.7%

Table 6-1. Distribution of samples by Laurén classification within The Cancer Genome
Atlas (TCGA) subtypes (Bass et al. 2014).

Diffuse
Intestinal
Mixed
Not Specified

Total
n
%
135 45.0%
146 48.7%
17
5.7%
2
0.7%

ACRG Classification
MSS/TP53- MSS/TP53+
MSI
n
%
n
%
n
%
42 39.3% 36 45.6% 20 29.4%
58 54.2% 38 48.1% 42 61.8%
7
6.5%
4
5.1%
5
7.4%
0
0.0%
1
1.2%
1
1.0%

MSS/EMT
n
%
37 80.4%
8 17.4%
1
2.2%
0
0.0%

Table 6-2. Distribution of samples by Laurén classification within The Asian Cancer
Research Group (ACRG) subtypes (Cristescu et al. 2015).
Similarly, though the cell of origin of gastric cancer is still not well-defined, the
data implicating Mist1+ as the cell of origin demonstrates that both sub-types can
originate from the same cell, albeit through different genetic manipulations (Hayakawa et
al. 2015). This is in contrast to cancers of other sites, where sub-types have been shown
to arise from distinct cells of origin either from similar or distinct genetic manipulations
(Blanpain 2013). Taken together with our data showing that diffuse-type and intestinaltype lesions can arise from the same genetic background, this might suggest that these
histologic classifications do not correlate with etiology of disease as well as was once
thought. Our work on the cell of origin of gastric cancer deserves further investigation.
Another caveat is the relative rarity of the specific genetic lesions we used to
generate our model. Kras mutations occur in only 9% of TCGA cases. However, as
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discussed in Chapter 1, if one looks at all members of the Epidermal Growth Factor
Receptor (EGFR)/Ras/Raf families, amplification or mutation occurs in >60% of cases
(Bass et al. 2014; Cerami et al. 2012). This analysis omits other Receptor Tyrosine
Kinases (RTKs) that can activate Kras. Likely the percentage of tumors with Kras
activation would only increase if other RTKs were considered. In fact, many RTKs have
been implicated in gastric carcinogenesis (Table 6-3). Because oncogenic Kras is a
common effector of many of these RTKs, it allows the modeling of RTK
amplification/mutation in general rather than that of one specific RTK. However, it does
not model all of the potential downstream effectors of RTKs. Nonetheless, one of its
favorable attributes is its common use and the wide array of literature on which one could
draw on while interpreting results.
Receptor Tyrosine Kinases (RTKs)
PDGFR
Platelet Derived Growth Factor Receptor
IGF-1R
Insulin-like Growth Factor-1 Receptor
TGFαR
Transforming Growth Factor α Receptor
EGFR
Epidermal Growth Factor Receptor
HER2 (ERBB2)
Human EGF Receptor 2
FGFR1
Fibroblast Growth Factor Receptor 1
FGFR2α
Fibroblast Growth Factor Receptor 2α
Insulin R
Insulin Receptor
EphA4
Erythropoietin-Producing Human Hepatocellular Receptor A4
FGFR2
Fibroblast Growth Factor Receptor 2
EGFR
Epidermal Growth Factor Receptor
HER2 (ERBB2)
Human EGF Receptor 2
HGFR(MET)
Hepatocyte Growth Factor Receptor

Reference
(Chung
and
Antoniades 1992)
(Gong et al. 2010)

(Deng et al. 2012)

Table 6-3. Receptor Tyrosine Kinases (RTKs) implicated in gastric carcinogenesis.
Additionally, though mutations in CDH1 are causal in hereditary diffuse gastric
cancer and loss of E-cadherin is common in sporadic diffuse-type gastric cancer, it is
rarely lost or mutated in intestinal-type gastric cancer (Liu et al. 2014). However, just as
we looked at the entire RTK/RAS/RAF pathway to argue the relevance of the inclusion
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of oncogenic Kras in our model, so should we do the same for E-cadherin related genes.
In fact, in the TCGA data set, one or more components of the adherens junction are
altered in 49% of gastric cancer cases (Figure 6-1) (Bass et al. 2014; Cerami et al. 2012).

Figure 6-1. Genetic alterations in adherens junction components in The Cancer Genome
Atlas (TCGA) gastric cancer cohort (Bass et al. 2014; Cerami et al. 2012).
Further, in the data available, from the cBioPortal, CDH1 and KRAS mutations or
other alterations rarely occur together in human gastric cancer (Bass et al. 2014; Cerami
et al. 2012). However, this may be explained by the interaction I propose here. If, for
example, a cell losses CDH1 expression it will also lose inhibition of the KRAS
downstream pathways, in effect activating these pathways. Thus there may not be
evolutionary pressure to gain oncogenic mutations of KRAS. Further it is known that, at
least in a pancreatic cancer model, oncogenic Kras inhibits E-cadherin (Rachagani et al.
2011). Thus, a cell that acquires a KRAS mutation may disinhibit itself by inhibiting Ecadherin, relieving the evolutionary pressure to mutate CDH1.
Finally, though our model metastasizes widely, it does not perfectly recapitulate
the distribution of metastasis observed in gastric cancer patients. Clinically, one does see
local lymph node involvement as we do in our model, but the most common sites of
spread are to the peritoneum and liver, while lung metastases are more rare (Avital et al.
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2015). That having been said, our model is the only clinically relevant model with
significant metastasis.	
  
Future Directions
The ACKPY model offers many avenues for future study, some of which I have
addressed in the previous chapters. First, an exploration of the role of oncogenic Kras in
the metastatic phenotype of our model is certainly pertinent. Whereas E-cadherin is
typically considered an invasion suppressor gene (Birchmeier, Hülsken, and Behrens
1995) here we see it functioning as a primary tumor suppressor. It is the addition of
oncogenic Kras to the Trp53/Cdh1 double-conditional knockout that expands the
metastatic range from rare micro-metastatic lesions of local lymph nodes (Shimada et al.
2012) to highly penetrant metastases to local lymph nodes, lungs, and mediastinal lymph
nodes, as well as rarer micro-metastases to the liver. More detailed analysis of livers may
reveal a higher frequency of metastases, as only 3 sections of tissue 200 µm apart were
analyzed from each liver, leaving much of the tissue uninvestigated. Further,
investigation of other tissues such as bone and the retroperitoneum might reveal other
sites of metastasis.
Study of the mixed-type histology of the model may reveal insights into the
differing etiology of intestinal- and diffuse-type lesions. This could be done through
experiments that isolate and compare lesions of differing histology. For example, laser
capture micro-dissection could be used followed by microarray, RNA-seq, or massspectrometric analyses.
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Much work can be done to further investigate the cell of origin of gastric cancer.
Initial experiments should seek to determine any overlap between Mist1+, Lgr5+, and
Atp4b+ cell populations; this could be performed easily by lineage tracing, coimmunostaining, or flow cytometry. I hypothesize that Mist1+ or Lgr5+ stem cell-derived
pre-parietal or parietal cells are the actual cell transformed in those models, and this
hypothesis could also be tested using lineage tracing experiments.
Finally, there are a variety of topics that could be studied using this model. I
performed a pilot experiment examining the involvement of the microbiome in the
development of gastric cancer in our mice. In a different pilot experiment, I observed a
correlation between number of circulating tumor cells and lung macrometastases. Both
these findings lay promising groundwork for validation and further study.
ii. E-cadherin as Gatekeeper to Mutant Kras and p53 Loss-Driven Gastric Cancer
Conclusions
I present evidence that E-cadherin may act as a gatekeeper to oncogenic Kras and
Trp53 loss-driven gastric cancer. I show that the presence of a wild-type Cdh1 allele in
our model delays oncogenesis significantly. Further, when tumors do form, they often
show loss of E-cadherin expression. While the preliminary data is intriguing, more
experiments need to be performed to definitively prove this hypothesis. As discussed, this
gatekeeper function is not without precedent, as the tumor suppressor APC acts similarly
in a colorectal cancer model (Dow et al. 2015). Of note, the other targeted model of
oncogenic Kras-driven gastric cancer also has deletion of APC (Hayakawa et al. 2015).
APC and E-cadherin functionality overlap in their regulation of β-catenin (Mohammed et
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al. 2016; Liu et al. 2014). One hypothesis that can be drawn from these data is that
canonical WNT signaling is necessary for oncogenic Kras and Trp53 loss-driven
tumorigenesis in the gut.
The other finding that resulted from adding wild-type Cdh1 back to our model
was the subcutaneous tumor phenotype. I initially assumed these lesions were metastases
resulting from gastric tumors. However, the fact that we did not detect primary tumors of
the stomach in the majority of the mice with subcutaneous tumors makes this
interpretation unlikely. The sarcomatoid histology of the tumors might suggest they are
not gastric in origin, but the gastric tumors that do rarely occur in these mice also have
sarcomatoid features. One cannot rule out the possibility of small, sarcomatoid stomach
lesions that metastasize early to the subcutaneous space.
I have come to favor the alternative explanation that these are sarcomas arising
from off-target Cre activity in the subcutaneous space. I present several additional pieces
of evidence that suggest this, including microarray data comparing these lesions to
human gastric cancer and sarcoma samples as well as analysis of expression of stomachspecific genes. Additionally, the latency to formation of these tumors is similar to that of
an oncogenic Kras and Trp53 loss-induced model of sarcoma (Kirsch et al. 2007).
Future Directions
Further investigation of E-cadherin as gatekeeper to oncogenic Kras and Trp53
loss-driven gastric cancer is certainly necessary. First, quantification of loss of Ecadherin in tumors arising in the Cdh1fl/+ and/or Cdh1+/+ must be performed. Second, the
mechanism of loss should be investigated. Additionally, comparisons of tumor areas to
81

non-tumor areas by microarray or RNA-seq may implicate signaling pathways that are
necessary for tumor formation. Comparison of tumor areas that have lost E-cadherin
expression and tumor areas that retain E-cadherin to non-tumor areas may be similarly
useful and reveal the changes, other than of E-cadherin loss, that allow tumor
progression. Finally, generating an E-cadherin loss allele that could be restored could
prove its gatekeeper status. One such model is a drug inducible shRNA knock-down as
was used in the APC/Kras/Trp53 colorectal cancer paper (Dow et al. 2015). Another
option is an XTR Cdh1 allele (Robles-Oteiza et al. 2015). Additionally, the hypothesis
that canonical WNT signaling is necessary for oncogenic Kras and Trp53 loss-driven
tumorigenesis in the gut could be tested in our model and/or in the APC/Kras/p53
colorectal cancer model by breeding the conditional β-catenin allele (Brault et al. 2001)
onto either model.
Finally, one could pursue definitive evidence on the origin of the subcutaneous
tumors that arise in the Cdh1fl/+ and Cdh1+/+ models. Evidence that they are sarcomas
could be derived from Atp4b-Cre;Rosa26LSL-YFP/ + mice. Detailed examination of the skin
by immunofluorescence for YFP expression and highly sensitive polymerase chain
reaction (PCR) for the recombined Rosa26LSL-YFP allele could reveal a rare Cre expressing
cell population in the subcutaneous space. Definitive proof of gastric origin (i.e. that they
are metastases) would be more difficult and likely involve lineage tracing using a second
marker of gastric or epithelial origin. Hypothetically, one could add a FLP recombinase
allele (CK19-FLP) driven by the cytokeratin 19 promoter and a FRT-STOP-FRT red
fluorescent protein (FSF-RFP) allele to the Cdh1fl/+ model. If the cutaneous tumors are
82

epithelial in lineage, they will fluoresce from both the RFP and YFP alleles. If they are
mesenchymal derived sarcomas, they should only fluoresce from the YFP allele.
iii. E-cadherin Loss Upregulates β-catenin Signaling in the ACKPY Mouse Model of
Gastric Cancer
Conclusions
I present, to my knowledge, the first evidence that E-cadherin loss leads directly
to the upregulation of β-catenin in vivo using microarray and qPCR for the upregulation
of TCF/LEF and canonical WNT targets, respectively. Additionally, I demonstrate a loss
of membranous β-catenin that correlates with loss of E-cadherin. I show that inhibition of
this pathway prolongs survival of our ACKPY mice. Further, I present the hypothesis that
this effect of E-cadherin loss is only possible in the context of oncogenic Kras
suppression of the β-catenin destruction complex. This potential in vivo evidence of such
crosstalk between oncogenic Kras and the canonical WNT pathway would itself be novel.
However, each of these findings has limitations that bear addressing.
First, the comparisons via microarray and qPCR were performed on whole
glandular stomach samples. These data leave open the possibility that the comparisons
may have been skewed by differential content of recombined tissue. For example, if the
Cdh1fl/fl stomachs are primarily composed of recombined tissue and the Cdh1fl/+ stomachs
have a lower content of recombined tissue, the comparison may be better characterized as
Cdh1fl/fl tumor versus normal stomach. This is unlikely given the high burden of
recombined tissue as observed by YFP staining (data not shown), but still a possibility.
An ideal experiment would compare only Cre recombined (YFP+) tissue from Cdh1fl/fl
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and Cdh1fl/+ mice. Unfortunately, my attempts to select for recombined cell populations
by fluorescence assisted cell sorting (FACS) for YFP+ cells did not yield high enough cell
numbers to extract good quality RNA. Alternatively, YFP+ areas could be selected by
laser capture micro-dissection. A less ideal but simpler possibility would be to include
YFP expression in the qPCR experiment and normalize the results to YFP content.
Second, while I present loss of membranous β-catenin in Cdh1fl/fl and Cdh1fl/+
tumors, I do not show a concomitant increase in cytoplasmic or nuclear β-catenin. This is
a common technical difficulty with immunofluorescence (IF) staining for β-catenin. One
solution might be to attempt to increase the sensitivity for β-catenin by adding a signal
amplification step to the protocol. Further, the use of immunohistochemical (IHC)
methods rather than IF might allow visualization of nuclear β-catenin. However, multiple
staining by IHC is problematic and not possible beyond two targets, so co-staining for Ecadherin and YFP, as I do with IF, would not be possible. Staining of serial sections is a
potential solution to this problem, though less elegant than co-staining.
Third, while I do show that administering a commonly used β-catenin/TCF
inhibitor (PKF118-310) prolongs survival of the ACKPY mice, I do not show that its
effects are on-target. This could be done by assaying for the expression of canonical
WNT targets in treated and untreated mice. However, the effect size of treatment with
PKF118-310 is so small that choosing an appropriate time point for such analysis could
be impossible. One might suggest increasing the dose of the inhibitor to improve the
effect size, however higher doses are not well-tolerated due to toxicity. As outlined in the
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previous section, addition of the conditional β-catenin allele to the model would show
dependence on β-catenin specifically.
Future Directions
In the previous section, I addressed several experimental improvements that
would more definitively show β-catenin upregulation due to E-cadherin loss in the
ACKPY model. There are several in vitro methods that would be of use if I were able to
isolate cell lines from both Cdh1fl/fl and Cdh1fl/+ stomach tissue. For example, expression
analysis could be done in these cell lines, luciferase reporter technology could be used to
show activity at β-catenin/TCF/LEF response elements, and nuclear localization of βcatenin could be shown by cell fractionation. However, we have been unable to isolate
cell lines from Cdh1fl/+ stomachs that are not fully transformed. One solution would be to
re-express E-cadherin in Cdh1fl/fl cells; however, there is little novelty to that experiment
as repression of β-catenin by E-cadherin expression is well-documented (Gottardi, Wong,
and Gumbiner 2001). Breeding a β-catenin reporter allele onto the Cdh1fl/fl and Cdh1fl/+
models could demonstrate direct regulation at the level of β-catenin/TCF response
elements. Maretto and colleagues generated such a construct utilizing the β-galactosidase
reporter (LacZ gene) under the control of β-catenin/TCF response elements (Maretto et
al. 2003).
To test the role of oncogenic Kras in this process, I would perform several
experiments. The first, and simplest, would utilize RNA already isolated from aged
ACPY (original double conditional model) stomachs, which should contain tumors that
lack oncogenic Kras but have E-cadherin knocked out. I would perform qPCR for
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canonical WNT targets in these samples alongside the Cdh1fl/fl and Cdh1fl/+ models.
Though limited by the caveats described above, if upregulation is not evident in the
ACPY stomachs then it would suggest a role for oncogenic Kras in the upregulation of
canonical WNT targets. This would have to be confirmed in experiments that examine
only at recombined (YFP+) tissue. I would include ACPY stomachs in any of the other
analyses listed above. Their inclusion in any of the studies that breed additional alleles
onto the model would be simple, as they are always generated during breeding of the
model. If my hypothesis that oncogenic Kras is necessary for upregulation of canonical
WNT signaling due to E-cadherin loss is correct, one would expect ACPY tumor
formation not to be dependent on β-catenin (in the conditional β-catenin allele
experiments) and not to show β-catenin reporter activity (in the β-galactosidase reporter
experiments). While in vitro methods would be of great use in testing this hypothesis, I
have not yet been able to generate cell lines from ACPY tumors. The use of knock-downs
(using shRNA technology) or knock-outs (using CRISPR technology) of oncogenic Kras
in ACKPY cell lines is a potential solution for use in vitro.
iv. Loss of E-cadherin Correlates with Upregulation of Oncogenic Kras Target
Genes in the ACKPY Mouse Model of Gastric Cancer
Conclusions
I present microarray data that shows that gene sets upregulated by Kras activity
are overrepresented in the set of genes upregulated in Cdh1fl/fl over Cdh1fl/+ stomachs.
Further, gene sets upregulated by several of the major downstream effectors of Kras are
also overrepresented. This is surprising given that both the Cdh1fl/fl and Cdh1fl/+ models
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express oncogenic Kras; one would expect similar Kras activity in these two models. One
interpretation of these data is that E-cadherin inhibits oncogenic Kras or its effector
pathways in the Cdh1fl/+ model. This hypothesis is intriguing given our data suggesting
that E-cadherin is a gatekeeper to oncogenesis in our model. While oncogenic Kras and
loss of Trp53 are sufficient to drive tumorigenesis in many other models, they are not so
in ours. Perhaps E-cadherin inhibition of oncogenic Kras is the mechanism behind this
gatekeeper function (Figure 6-2). Finally, given the data on APC in the Kras/Trp53
colorectal cancer model (Dow et al. 2015), the common regulation of β-catenin by APC
and E-cadherin may mediate this inhibition throughout the gut.
These findings and hypotheses are not without caveats. As described in the
previous section, the microarray data is limited by the use of whole glandular stomach
samples. Further, the microarray data showed overrepresentation of MAPK upregulated
gene sets in our set of genes upregulated in Cdh1fl/fl over Cdh1fl/+ stomachs. However,
these findings were not indicative of E-cadherin regulation of the MAPK pathway as
assayed by pERK abundance.
One further caveat is the possibility that even though Cdh1fl/+ stomachs appear to
possess a high content of recombined cells, these cells may not be cycling as rapidly as
those in the frank tumors of Cdh1fl/fl stomachs. Thus, Kras downstream signaling would
be artifactually lower in Cdh1fl/+ recombined cells compared to Cdh1fl/fl recombined cells.
This difference would still be due to the presence or absence of a wild-type Cdh1 allele.
However, it may indicate a different mechanism of decreased tumor formation than the
interaction between E-cadherin and Kras that I propose. Future experiments would,
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ideally, also show equivalent proliferative activity of these cells either qualitatively by
Ki67 staining, or quantitatively by BrdU incorporation. In an attempt to address this issue
in the microarray I examined the expression of Mki67 and Pcna. Notably, Mki67
expression was not statistically significantly different between Cdh1fl/+ and Cdh1fl/fl
stomachs. Whereas Pcna was actually up by 63.6% in Cdh1fl/+ over Cdh1fl/fl stomachs (qvalue=1.48%).

Figure 6-2. Hypotheses related to E-cadherin loss in the ACKPY model.
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Future Directions
Though I observed no difference in ERK activation between the Cdh1fl/fl and
Cdh1fl/+ models, E-cadherin may still be regulating other pathways downstream of
oncogenic Kras. The microarray data identified the PI3K, NF-κB, and NFAT pathways as
other possible targets/mechanisms. Using IF or IHC, I would assay for the activation of
the PI3K pathway via phopsho-AKT, for NF-κB nuclear versus cytoplasmic localization
or phospho-p65 content, and for NFAT nuclear versus cytoplasmic localization in
Cdh1fl/fl and Cdh1fl/+ tissues. Additionally, it may be worth repeating the microarray
experiment using RNA isolated only from YFP+ areas in the Cdh1fl/fl and Cdh1fl/+ models
(as discussed earlier, either by FACS or laser capture micro-dissection). Doing so would
reduce background signal from non-parietal cell tissue. Further, I would ensure that all
Cdh1fl/+ tissue was derived from stomachs that lacked tumor by saving a portion of the
stomach for histologic analysis.
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APPENDIX 1 MATERIALS AND METHODS
i. Animals
The University of Pennsylvania Animal Care and Use Committee approved all
animal studies. Parental mouse strains, background, source, genotyping, and primary
reference are available in Table 0-1.
Allele
Atp4b-Cre

Background
B6.FVB(N1)

Source
Gordon Lab
Washington University in St.
Louis

Cdh1fl

B6.129(N3)

The Jackson Laboratory (005319)

KrasLSL-G12D

B6.129(N10)

Trp53fl

B6.129(N10)

Tyler Jacks Laboratory
Massachusetts Institute of
Technology
(backcrossed to C57BL/6 in the
Ryeom Laboratory)
Tyler Jacks Laboratory
Massachusetts Institute of
Technology
(backcrossed to C57BL/6 in the
Ryeom Laboratory)
Stanger Lab
Perelman School of Medicine at
the University of Pennsylvania

Rosa26LSLYFP

B6.129(N?)

Genotyping
5’-CAGCGGAGGGCAGATAGCAAGCAAG
5’-CCGGTTATTCAACTTGCACC
411 bp Transgene
5’-GGGTCTCACCGTAGTCCTCA
5’-GATCTTTGGGAGAGCAGTCG

Reference
(Syder et
al. 2004)
(Boussadia
et al.
2002)

243 bp Wild-type/310 bp Mutant
5’-GCAGGTCGAGGGACCTAATA
5’- TGTCTTTCCCCAGCACAGT
5’-CTGCATAGTACGCTATACCCTGT

(Jackson
et al.
2001)

250 bp Wild-type/100 bp Mutant
5’- GGTTAAACCCAGCTTGACCA
5’- GGAGGCAGAGACAGTTGGAG

(Marino et
al. 2000)

270 bp Wild-type/390 bp Mutant
5’- AAAGTCGCTCTGAGTTGTTAT
5’- GGAGCGGGAGAAATGGATATG
5’-AAGACCGCGAAGAGTTTGTC

(Srinivas
et al.
2001)

600 bp Wild-type/320 bp Transgene

Table 0-1. Mouse strains used to generate ACKPY mice.
ACKPY Breeding
Over the course of six generations I crossed these 5 alleles into two parental
strains: ACPY (Atp4b-Cre;Cdh1fl/fl;Trp53fl/fl;Rosa26LSL-YFP/LSL-YFP) and CKPY (KrasLSLG12D/+

;Cdh1fl/fl;Trp53fl/fl;Rosa26LSL-YFP/LSL-YFP). When interbred, these lines produced 3

useful genotypes: ¼ are the desired ACKPY; ¼ are the first breeder genotype, ACPY;
and ¼ are the second breeder genotype, CKPY (Figure 0-1). Of note, the ACPY group is
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the double conditional knockout of Cdh1 and Trp53, from Shimada et al 2012, with the
addition of conditional YFP expression.
fl/fl

fl/fl

Atp4b-Cre;Cdh1 ;Trp53 ;Rosa26
fl/fl

LSL-YFP/LSL-YFP

Cdh1 ;Kras

¼
¼
¼

fl/fl

LSL-G12D/+

LSL-G12D/+

(ACPY)
fl/fl

;Trp53 ;Rosa26

fl/fl

LSL-YFP/LSL-YFP

(CKPY)

LSL-YFP/LSL-YFP

Atp4b-Cre;Cdh1 ;Kras
;Trp53 ;Rosa26
ACKPY Model of Gastric Cancer
fl/fl
+/+
fl/fl
LSL-YFP/LSL-YFP
Atp4b-Cre;Cdh1 ;Kras ;Trp53 ;Rosa26
ACPY Shimada et al Double Conditional Model (and Breeder)
fl/fl
LSL-G12D/+
fl/fl
LSL-YFP/LSL-YFP
Cdh1 ;Kras
;Trp53 ;Rosa26
CKPY, Cre- control for ACKPY (and Breeder)

Figure 0-1. Breeding scheme to derive ACKPY mice and relevant controls.
Cdh1fl/+ and Cdh1+/+ Breeding
To investigate the dependence of our ACKPY model on Cdh1 loss I bred one or
two alleles of wild-type Cdh1 back onto the ACKPY mice. These Cdh1fl/+ and Cdh1+/+
mice
G12D/+

were

bred

by

crossing

ACPY

mice

to

KPY

mice

(KrasLSL-

;Trp53fl/fl;Rosa26LSL-YFP/LSL-YFP) mice for one or more generations.

Survival Analysis
For ACKPY mice, end point was reached at natural death or humane euthanasia at
loss of 20% maximum body weight. To account for the mixed background, ten
independent breeding pairs were utilized, each contributing two sibling pairs of ACKPY
and ACPY mice (excepting one breeding pair that only contributed one ACPY sibling).
For Cdh1fl/+ and Cdh1+/+ mice, end point was reached at natural death or humane
euthanasia at loss of 20% maximum body weight. Animals that required humane
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euthanasia for subcutaneous tumor burden > 2 cm3 were censored in the analysis. To
account for the mixed background, at least 10 independent breeding pairs were utilized in
generating the cohorts.
Metastatic Analysis
Ten of the ACKPY mice from the survival cohort were analyzed for metastases.
Epigastric fat, liver, lungs, and any abnormal lesions were dissected and analyzed (see
Histology and Immunofluorescence).
Analysis of Disease Progression
Five ACKPY and five CKPY matched Cre negative control mice were sacrificed
at 3, 6, and 9 weeks. To account for mixed background, five independent sets of ACKPY
and CKPY negative control mice were used from five independent breeding pairs.
Stomachs were dissected out and analyzed (see Histology and Immunofluorescence).
In vivo Drug Treatments
Drug treatments were initiated in 4-week-old mice ACKPY mice. MEK inhibitor
(PD0325901, APExBIO) was administered ad libitum in the mouse chow (Purina 5010)
at 7 mg/kg (incorporation by Research Diets Inc.). PKF118-310 (EMD Millipore) was
administered 3x weekly as an IP injection of a 0.1 mg/mL solution in 0.1% DMSO at a
dose of 1 mg/kg, control mice received volumetrically equivalent doses of 0.1% DMSO
via IP injection. Mice were analyzed for survival (see Survival Analysis).
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Intra-tracheal AdenoCre Inoculation
Viral precipitates were formed by mixing 2.5x107 pfu of AdenoCre (University of
Iowa Viral Vector Core Facility) and 0.6 μmoles CaCl2 (Sigma) to a total volume of 60
μL in DMEM (Gibco) per mouse and incubating at room temperature for 10 minutes.
Mice of the indicated genotypes were anesthetized, intubated with a 22 g angiocatheter,
and inoculated with 60 μL of viral precipitates via the catheter.
v. Microbiome Study
Microbiome Depletion
Microbiome depletion was achieved by antibiotic administration via the drinking
water ad libitum at 1 g/L ampicillin (Polyflex, Boehringer Ingelheim Vetmedica, Inc), 1
g/L neomycin (NeoMed 325, Bimeda Inc), 1 g/L metronidazole (Watson Pharma Inc.),
0.5 g/L vancomycin (vancomycin hydrochloride, Mylan Institutional LLC), and 4 g/L
sucralose (Splenda, McNeil Nutritionals, LLC).
Quantification of Microbiome Depletion
At necropsy gastric contents and cecal contents were flash frozen. DNA was
extracted from 50-300 mg of gastric or cecal contents using the QIAamp Fast DNA
Stoool Mini Kit (QIAGEN) according to the manufacturers instructions. qPCR was
performed on a ViiA 7 Real-Time PCR System (Thermo Fisher Scientific) using SYBR
Green PCR Master Mix (Thermo Fisher Scientific) according to the manufacturers
directions

using 20 ng of stomach or cecal content DNA per 10 μL reaction.

Amplifications were performed as technical triplicates and biological quadruplicates.
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Generic 16S rRNA primers 5’-ACTCCTACGGGAGGCAGCAGT (UniF340) and 5’ATTACCGCGGCTGCTGGC (UniR514) were used for amplification (Barman et al.
2008).
vi. Detect of Circulating Tumor Cells
Blood Collection and RBC Lysis
A 1 mL insulin syringe (BD #329412) was coated with 1 mg/mL heparin (Sigma
#H3149-250KU) in PBS (Sigma #D5652-10X1L). As much blood as possible was
collected by cardiac puncture and transferred to an EDTA coated tube (BD #367841).
The remainder of the procedure was carried out in the dark. 100-200 ul of blood was
RBC lysed by the addition of 5 volumes of RBC lysis buffer (G-Biosciences #786-650)
and incubated at room temperate for 5 min with mixing. FACS buffer (PBS + 5% FBS +
2 mM EDTA) was added to the lysis reaction up to 3 mLs, mixed, and centrifuged at
2400 x g for 5 min. The supernatant was removed and the cell pellet resuspended in 100
ul FACS Buffer.
CD45 Staining and Flow Cytometric Analysis
1 ul of anti-CD45-APC (Biolegend	
   #103112) was added to 100 ul of suspended
cells, mixed and incubated in the darkat room temperature for 15 min. To wash, 500 ul of
FACS buffer was added, the suspension mixed, centrifuged at 400 x g for 5 min, and the
supernatant discarded. The cell pellet was resuspended in 300-500 ul FACS buffer.
Immediately prior to flow cytometric analaysis 2 ul of 5 mg/mL DAPI (ThermoFisher
Scientific #D1306) was added to the cell suspension and mixed for live/dead
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discrimination. The samples were run on a BD FACSVerse flow cytometer and CTCs per
sample were quantified (defined as DAPI-, CD45-, YFP+).
vii. Histology
Tissue Preparation
Tissues were dissected from indicated mice, fixed in 10% formalin in phosphate
buffered saline (PBS), and dehydrated. Stomachs were opened along the greater
curvature, washed of contents in PBS, the forestomach stomach was removed, and the
glandular stomach cut into two or three levels to be embedded together. The Abramson
Family Cancer Research Institute (AFCRI) histology core facility embedded the tissues
in paraffin, sectioned them at 5 um, and provided me with unstained slides or stained
them with hematoxylin and eosin (H&E).
Immunofluorescence
Unstained sections were warmed to 55 C, de-waxed in two xylene washes for 10
minute each, and rehydrated through an ethanol gradient (100%, 100%, 95%, 70%, 50%,
0%, 0%, 0%, 5 minutes each). Antigen retrieval was performed in a 2100 Retriever
(Aptum Biologics Ltd.) using Antigen Unmasking Solution (Vector Labs). Samples were
then washed three times in H2O and equilibrated to phosphate buffered saline (PBS), 5
minutes each. They were then permeabilized in 0.2% Triton-X in PBS for 45 minutes.
Sections were washed three times with PBS and treated with blocking solution (10% goat
serum and 1% bovine serum albumin in PBS) for 1 hour. Hybridization of non- mouse
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primary antibodies was performed overnight in blocking solution at 4 C (see Table 0-2
for antibody information and dilutions).
For mouse antibodies, sections were triple washed with PBS for 5 min each then
blocked with Streptavidin/Biotin Blocking Kit (Vector Labs): sections were incubated
with streptavidin solution for 15 minutes, washed twice with PBS for 5 min each, and the
incubation and washes repeated with biotin solution. Hybridization of mouse primary
antibody (see Table 0-2 for antibody information and dilutions) was done using the
Mouse on Mouse (M.O.M.) Basic Kit (Vector Labs): sections were incubated for 1 hour
in M.O.M. Mouse Ig Blocking Reagent, washed twice in PBS for 2 minutes each,
equilibrated to M.O.M. Diluent for 5 minutes, treated with primary antibody in M.O.M.
Diluent for 30 minutes at room temperature, washed twice in PBS for 2 minutes, and
incubated with M.O.M. Biotinylated Anti-Mouse IgG Reagent in M.O.M. Diluent for 10
minutes.
For non-mouse antibodies or continuing after hybridization to mouse antibody,
sections were triple washed with PBS for 5 min each and then incubated with secondary
antibody diluted 1:1000 in 1% bovine serum albumin in PBS for 2 hours at room
temperature. They were again triple washed with PBS for 5 min each and mounted with
Fluor-Gel II with DAPI (Electron Microscopy Sciences).
Target

Company

Catalog #

Dilution

Host

YFP (anti-GFP)

Abcam

ab13970

1:1000

Chicken

E-cadherin

BD

610181

1:1000

Mouse

β-catenin

CST

8480

1:100

Rabbit

pERK

CST

4370

1:200

Rabbit

Secondary
(Thermo Fisher Scientific Catalog #)
anti-Chicken Alexa Fluor 488
(A-11039)
AlexaFluor 555 conjugated Streptavidin
(S-21381)
anti-Rabbit Alexa Fluor 594
(A-21207)
anti-Rabbit Alexa Fluor 594
(A-21207)

Table 0-2. Antibody information for immunofluorescence staining.
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Immunohistochemistry
Unstained sections were warmed to 55 C, de-waxed in two xylene treatments for
10 minute each and rehydrated through an ethanol gradient (100%, 100%, 95%, 70%,
50%, 0%, 0%, 0%, 5 minutes each). Antigen retrieval was performed in a 2100 Retriever
(Aptum Biologics Ltd.) using Antigen Unmasking Solution (Vector Labs). Samples were
then washed three times in H2O and further washed and permeabilized in Tris Buffered
Saline (TBS, BioRad) + 0.25% Tween (BioRad), referred to as TBST, for two washes of
5 minutes each. Sections were treated with blocking solution (10% goat serum and 1%
bovine serum albumin in TBST) for 1 hour. Hybridization of with primary antibody was
performed overnight in blocking solution at 4 C (see Table 0-3 for antibody information
and dilutions).
Sections were washed twice with TBST and once with TBS, 5 minutes each, and
endogenous peroxidases oversaturated by incubation with 0.3% H2O2 in TBS. Samples
were triple washed with TBST, 5 minutes each, and hybridized to secondary antibody
(see Table 0-3) in blocking buffer for 1 hour at room temperature. Enzymatic detection
was performed using the Vectastain ABC HRP Kit (Vector Labs) and DAB Peroxidase
(HRP) Substrate Kit (Vector Labs). Sections were triple washed with TBST, double
washed with TBS (5 minutes each) and hybridized to Vectastain ABC HRP reagent
(prepared according to manufacturers instructions) for 30 minutes at room temperature.
Slides were again washed twice with TBST and twice with TBS, 5 min each, and then
incubated with DAB Substrate (prepared according to manufacturers instructions) for the
time indicated in Table 0-3. Washing with H2O stopped reaction. Samples were then
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counterstained in Hematoxylin (50:50 solution in H2O) for 3 minutes at room temperature
and washed under running H2O for 5 minutes. Slides were dehydrated through a series of
ethanol solutions (80%, 95%, 100%. 100%) for 5 minutes each and two xylene washes of
20 minutes each. Sections were mounted using PROTOCOL SecureMount (Fisher) and
coverslips.
Target

Company

Catalog#

Dilution

Host

pERK
Isotype

CST
CST

4370
3900

1:200
1:2000

Rabbit
Rabbit

Secondary
Dilution (Company & Catalog #)
Biotinylated Goat Anti-Rabbit IgG Antibody
1:200 (Vector Labs BA-1000)

Time to
Develop
190 sec

Table 0-3. Antibodies for immunohistochemical staining.
Image Acquisition
Bright field and epifluorescence images were acquired on a Leica DMI6000B microscope
and processed using the LAS-AF software or a Zeiss Axio Imager.M2 microscope and
processed using the ZEN 2 software. Confocal images were acquired on a Leica TCS SP5
laser scanning confocal microscope and processed using the LAS-AF software.
viii. Cell Lines
Derivation
Indicated tissue was harvested from mice that had reached humane end-point. Tissues
were minced and digested in collagenase II (2.5 mg/mL, Worthington) and DNase (0.5
mg/mL, Worthington) in HBSS (Gibco) at 37 C for 45 minutes. Alternatively, tissue and
collagenase II/DNase solution were placed in a C tube (Miltenyi Biotec) and a single cell
suspension was generated using a gentleMACS Octo Dissociator with Heaters program
“37_m_TDK_1” (Miltenyi Biotec). Excess Fetal Bovine Serum (FBS, Hyclone) was
added to quench enzymes and digested tissue was pelleted by centrifugation. Pellet was
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resuspended and plated in normal growth medium: Advanced DMEM (Cellgro) + 10%
FBS + Penicillin/Streptomycin (Lonza) + L-glutamine (Gibco). After 24 hours incubation
at 37 C under 5% CO2, adherent cells were washed three times with phosphate buffered
saline (PBS, Sigma) and medium replaced.
Passaging of Cell Lines
Cell lines were maintained in Advanced DMEM (Cellgro) + 10% FBS +
Penicillin/Streptomycin (Lonza) + L-glutamine (Gibco) on tissue culture treated plastic in
37 C incubators under 5% CO2. Sub-cultivation was performed by washing adherent cells
with PBS and incubating with 0.25% Trypsin-EDTA (Gibco) until detached. Trypsin was
quenched by the addition of excess complete medium. Cells were re-plated at a subculture ratio of 1:5 or higher.
Flank Tumor Formation
Cell lines were sub-cultured for several passages prior to use. Cells were harvested with
0.25% Trypsin-EDTA, quenched with excess FBS, washed with PBS, and injected
subcutaneously in the flank at 5x106 cells per 0.1 cc PBS per mouse. Tumors were
measured every 2-3 days using digital calipers (Fisher) and tumor volume calculated as
(0.5)*(width2)*(length). For experimental model of metastasis, flank tumors were
resected under sterile conditions when tumor volumes were approximately 500 mm3.
Mice were euthanized and lung tissue analyzed for metastasis three weeks post resection.
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ix. Gene Expression Analysis
RNA isolation
Glandular stomachs were dissected from indicated mice, homogenized using a
gentleMACS Dissociator with M tubes (Miltenyi Biotec) in QIAzol Lysis Reagent
(Qiagen), and RNA isolation performed using the RNeasy Microarray Tissue Mini Kit
with optional DNase treatment (Qiagen) according to the manufacturers protocols.
Quantification of total RNA was performed on a NanoDrop (Thermo Fisher Scientific).
Microarray Target Preparation and Hybridization
The UPENN Molecular Profiling Facility provided microarray services, including
quality control tests of the total RNA samples by Agilent Bioanalyzer and Nanodrop
spectrophotometry. All protocols were conducted as described in the Affymetrix WT Plus
Reagent Kit Manual and the Affymetrix GeneChip Expression Analysis Technical
Manual. Briefly, 250ng of total RNA was converted to first-strand cDNA using reverse
transcriptase primed by poly(T) and random oligomers that incorporated the T7 promoter
sequence. Second-strand cDNA synthesis was followed by in vitro transcription with T7
RNA polymerase for linear amplification of each transcript, and the resulting cRNA was
converted to cDNA, fragmented, assessed by Bioanalyzer, and biotinylated by terminal
transferase end labeling. Five and a half micrograms of labeled cDNA were added to
Affymetrix hybridization cocktails, heated at 99ºC for 5 min and hybridized for 16 h at
45ºC to Mouse Transcriptome 1.0 ST GeneChips (Affymetrix Inc., Santa Clara CA)
using the GeneChip Hybridization oven 645. The microarrays were then washed at low
(6X SSPE) and high (100mM MES, 0.1M NaCl) stringency and stained with
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streptavidin-phycoerythrin. Fluorescence was amplified by adding biotinylated antistreptavidin and an additional aliquot of streptavidin-phycoerythrin stain. A GeneChip
3000 7G scanner was used to collect fluorescence signal. Affymetrix Command Console
and Expression Console were used to quantitate expression levels for targeted genes;
default values provided by Affymetrix were applied to all analysis parameters.
Principle Component Analysis, Hierarchical Clustering, and Heat Maps
Principle Component Analysis was performed using Expression Console Software
(Affymetrix). The Penn Genomic Analysis Core Bioinformatics group performed
unsupervised hierarchical clustering of Cdh1fl/fl and Cdh1fl/+ stomach tissue expression
data using Partek Genomics Suite (Partek Inc). Hierarchical clustering and heat map
production for Cdh1fl/+ stomach and subcutaneous tumor expression data was performed
using GenePattern 2.0 Software (Reich et al. 2006): HierarchicalClustering (Eisen et al.
1998), HierarchicalClusteringViewer, and HeatMapViewer modules.
Differential Gene Expression Analysis
Differentially expressed genes were determined using the Transcriptome Analysis
Console (TAC) Software (Affymetrix) with a FDR q-value cut-off of 5% and a foldchange cut-off of 2.
Gene Set Overlap Analysis
Differentially expressed mouse genes were manually mapped to their human homologs
using the HomoloGene database (http://www.ncbi.nlm.nih.gov/homologene) from the
National Center for Biotechnology Information (NCBI) (Geer et al. 2010). Gene set
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overlaps were computed for gene lists using the Investigate Gene Sets function
(http://software.broadinstitute.org/gsea/msigdb/annotate.jsp) on the Gene Set Enrichment
Analysis page of the Broad Institute (Subramanian et al. 2005).
Quantitative Real-Time Polymerase Chain Reaction (qPCR)
Complementary DNA (cDNA) was synthesized using the High Capacity cDNA Reverse
Transcription Kit (Thermo Fisher Scientific) according to the manufacturers directions
with 2 μg RNA per 10 μL reaction. qPCR was performed on a ViiA 7 Real-Time PCR
System (Thermo Fisher Scientific) using SYBR Green PCR Master Mix (Thermo Fisher
Scientific) according to the manufacturers directions using 0.5 μL cDNA per 10 μL
reaction. Amplifications were performed as technical quadruplicates and biological
sextuplicates. Values were normalized to HPRT expression. Mouse gene-specific primers
(Table 0-4) were selected from PrimerBank (X. Wang and Seed 2003; Spandidos et al.
2008; Spandidos et al. 2010).
Gene

Forward Primer

Reverse Primer

Hprt
Myc
Ccnd1
MMP7
Axin2
Lef1
Cd44v1

5’-TCAGTCAACGGGGGACATAAA
5’-ATGCCCCTCAACGTGAACTTC
5’-GCGTACCCTGACACCAATCTC
5’-CTGCCACTGTCCCAGGAAG
5’-TGACTCTCCTTCCAGATCCCA
5’-TGTTTATCCCATCACGGGTGG
5’-CACCATTGCCTCAACTGTGC

5’-GGGGCTGTACTGCTTAACCAG
5’-CGCAACATAGGATGGAGAGCA
5’-CTCCTCTTCGCACTTCTGCTC
5’-GGGAGAGTTTTCCAGTCATGG
5’-TGCCCACACTAGGCTGACA
5’-CATGGAAGTGTCGCCTGACAG
5’-TTGTGGGCTCCTGAGTCTGA

Amplicon
Size
142 bp
228 bp
183 bp
175 bp
105 bp
67 bp
116 bp

PrimerBank
ID
7305155a1
27545183a1
6680868a1
6754716a1
31982733a1
27735019a1
6491804a1

Table 0-4. Quantitative Real-Time Polymerase Chain Reaction Primers.
x. Quantification and Statistics
Lung Tumor Area Quantification
Area quantification was performed using Fiji (Schneider, Rasband, and Eliceiri 2012;
Schindelin et al. 2012; Schindelin et al. 2015) image analysis software using the Adjust
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Threshold Color (Thresholding method: Default, Color space: HSB), Select, and Measure
functions. Tumor area settings were Hue 205-231, Saturation 40-120, and Brightness 90225. Total lung area settings were Hue 0-255, Saturation 0-255, and Brightness 0-184.
Data is represented as tumor area divided by total lung area for one section containing at
least 4 of 5 lung lobes.
pERK Immunofluorescence Quantification
Area quantification was performed using Fiji (Schneider, Rasband, and Eliceiri 2012;
Schindelin et al. 2012; Schindelin et al. 2015) image analysis software using the Adjust
Threshold Color, Select, and Measure functions. pERK and YFP overlap area settings for
Adjust Color Threshold (Thresholding method: Default, Color space: HSB) were Hue 4050, Saturation 0-225, and Brightness autoset by program (with “Dark background” radio
button selected). YFP area settings for Adjust Color Threshold (Thresholding method:
Default, Color space: Lab) were L* auto-set by program, a* 0-150, and b* 0-225 (with
“Dark background” radio button selected). Data is represented as pERK and YFP overlap
area divided by YFP area for 1-2 images per tissue level over 2-3 tissue levels per
sample.
pERK Immunohistochemistry Quantification
Area quantification was performed using Fiji (Schneider, Rasband, and Eliceiri 2012;
Schindelin et al. 2012; Schindelin et al. 2015) image analysis software using the Adjust
Threshold Color (Thresholding method: Default, Color space: HSB), Select, and Measure
functions. pERK staining area settings were Hue 0-40, Saturation 0-255, and Brightness
0-184. Total stomach tissue area settings were Hue 0-255, Saturation 0-255, and
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Brightness 0-184. Data is represented as pERK staining area divided by total stomach
tissue area for 2-3 tissue planes.
Statistics
Statistical analyses (other than those previously described for microarray analysis) were
performed in Prism 5 (GraphPad Software). Survival analysis p-values were calculated
using the Log-rank (Mantel-Cox) test. All other p-values were calculated using the
student’s t-test (unpaired, two-tailed).
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